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1.1 HIV-1  
1.1.1 The Epidemiology of HIV-1 
By the end of 2011, the Joint United Nation program on HIV/ AIDS (UNAIDS) estimated that 
34 million people were living with HIV worldwide http://www.avert.org/aidsSouthAfrica. An 
estimated 2.5 million had become infected with HIV while 1.7 million people were estimated to 
have died of AIDS related causes. However, the epidemic of HIV continues to differ between 
countries and regions. Sub-Saharan Africa is one of the regions most affected by HIV-1, with an 
estimate of 23.5 million people living with HIV-1. South Africa still remains the country with 
the highest number of HIV-1 infected people with an estimate of 5.6 million by the end of 2011 
(UNAIDS special report 2013). During the same year, the number of infected people who died 
from HIV/AIDS related causes reduced from 310 000 in year 2009 to 270 190 in 2011 
http://www.avert.org/aidsSouthAfrica .  
The HIV-1 prevalence in SA is 17.3 % but it varies greatly by province. KwaZulu –Natal has the 
highest prevalence (15.8%), mainly in the 15-49 year old age group. Western Cape and Northern 
Cape are the least affected provinces with percentage of 3.8% and 5.9% respectively 
http://www.avert.org/aidsSouthAfrica .  
1.1.2 The Classification of HIV-1 and geological distribution 
Human immunodeficiency virus (HIV) is subdivided into two types: the HIV-1 and HIV-2  
 (Cohen et al., 2008). HIV -1 has been postulated to have originated from three cross species 
transmissions of simian immunodeficiency virus (SIV) which infected chimpanzees while HIV-2 
is thought to have originated from the sooty mangabey monkey (Lihana et al., 2012). HIV-1 
genetic diversity is classified into groups: Major (M), Outlier (O) and N (non-M/N), subtypes, 
sub-subtypes and circulating recombinant forms (CRFs). This classification is based on 
phylogenic sequences from the HIV-1 genome (pol, gag, env) (Jülg and Goebel, 2005, Paraschiv 
et al., 2007, Wainberg, 2004). Recently, a new Putative group designated P was described in 
Cameroonian patients and has not shown evidence of recombination with other HIV-1 subtypes 
(Lihana et al., 2012, San Mauro and Agorreta, 2010).   
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Group M is the most common cause of HIV-1 infection worldwide and has nine subtypes A, B, 
C, D, F, G, H, J and K (Jülg and Goebel, 2005, Paraschiv et al., 2007). It has been reported that 
48% of the infections are caused by Subtype C, followed by 12% caused by subtype A, 11% by 
subtype B, 5% by subtype G, 2% by subtype D and 22% caused by recombinants (Lihana et al., 
2012).  Subtype C is found largely in Southern and Eastern Africa, while Subtype A, which is 
further sub dived into A1, A2, A3, A4, and A5, is found mostly in East Africa (Lihana et al., 
2012). Subtype D is also found in East Africa while Subtype B has been found to be stable in 
Northern Africa and is more common in the Western world (Soares et al., 2007). Subtype F 
which is sub dived into F1 and F2 occurs in Central Africa, South America and Eastern Europe 
(Jülg and Goebel, 2005, Wainberg, 2004). Subtype G and A/G recombinants also occur in 
Eastern Africa and in Central Europe, while H and K only occur in Central Europe. Subtype J 
has been found in Central America (Wainberg, 2004).  The circulating recombinants forms occur 
due to recombination between subtypes occurring mainly in dually infected patients. 
Recombinants such CRFO2 _AG and CRFO6_CPX are predominant in Western Africa (Lihana 
et al., 2012). 
Group N is a very distinctive form of virus that has only been identified in a few individuals in 
Cameroon and subtypes within this HIV-1 group are not yet clearly defined. Group O has very 
diverse viruses, but it is rarely found. Also, subtypes within O group are not yet fully defined 
(Lihana et al., 2012). The Geological distribution of the HIV-1 subtypes is illustrated in figure 2 
below:  
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Figure 1.1: Geological distribution of HIV-1 subtypes. This distribution shows the most prevalent 
HIV-1 subtypes and their geological distribution. Source: 
(http://www.medscape.org/viewarticle/583361_2). 
1.1.3 The Structure of HIV-1  
The HIV-1 virions are spherical in shape and possess a lipid bilayer membrane that surrounds the 
viral Env glycoprotein and some cellular proteins (Sierra et al., 2005). The Env glycoprotein is a 
heterodimer of the gp120 which is attached to the gp41 (transmembrane glycoprotein). The 
structural proteins that form the core are: Matrix (MA/p17), capsid (CA/p24), Nucleocapsid 
(NC/p7) and p6. The MA forms a shell that connects directly to the inner side of the membrane. 
The capsid has the N- terminal domains that are arranged in hexameric ring to form a capsid. The 
NC is involved in the formation and stabilization of the of the genomic RNA dimers and in the 
nucleocapsid assembly. The p6 is the domain of p55 and is essential for the last stage of viral 
assembly as well as the release of the vpr protein into the assembled virion. The gp120 encloses 
the CD4- receptor binding domain as well as the coreceptor binding site (Sierra et al., 2005). 
  6 
 
 
Figure 1.2: The structure of HIV-1. Source: (www.stanford.edu/.../ret_6_gpedesc.html )  
The HIV genome is made up of two single stranded RNA molecules which are 9.2kb in size. It 
has four main regions: the LTR, gag-pol gene, env gene and the accessory genes (Figure 1.3) 
(Sierra et al., 2005). LTR is a regulatory region that contains the U3, R and U5 regions. The gag-
pol gene consists of the Gag polyprotein that comprises the proteins of the nucleocapsid. It also 
consists of the gag –pol polyprotein that compromises some structural proteins and the viral 
enzymes: protease (PR), reverse transcriptase (RT), and integrase (IN). The env gene encodes the 
gp160 polypeptide precursor that consists of the exterior gp120 and the transmembrane gp41. 
The tat, rev, rev, nef, vif, vpr and vpu are accessory genes that codes for proteins that control the 
HIV to infect the cell and to produce new copies of the virus (Sierra et al., 2005). 
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Figure 1.3: The structure illustrating the organization of the HIV-1 genome. Source 
http://hivbook.com/tag/viral-genome/  
1.1.4 The Life Cycle of HIV-1 
The first step in the life cycle of HIV-1 is the viral attachment. The HIV-1 envelope gp120 binds 
to the CD4 cell receptor (Arts and Hazuda, 2012). The interaction of the gp120 and the CD4 is 
followed by the binding to the CC chemokine receptor such as the CCR5 or CXCR4. These 
receptor binding causes the conformational change in the gp120 which uncovers a hydrophobic 
domain on the gp41 that facilitates fusion with the cell membrane thus allowing the uncoating of 
viral core into the host cell cytoplasm (Arts and Hazuda, 2012). The reverse transcriptase 
enzyme converts the single stranded RNA into double stranded DNA (Arts and Hazuda, 2012, 
Singh et al., 2010). The cDNA is then transported to the nucleus where the viral DNA is 
integrated with the host cell DNA by the enzyme integrase (Arts and Hazuda, 2012, Craigie and 
Bushman, 2012).  
After integration, the provirus is transcribed by the RNA Polymerase II into mRNAs (Sierra et 
al., 2005).  The mRNAs are translated into structural components, enzymes and genomic RNA 
which are transported to the cellular membrane and assemble. Immature virions are released 
(Sierra et al 2005). The viral PR cleaves the Gag and Gag pol polyprotein into mature Gag and 
Pol proteins (Sierra et al., 2005). The life cycle of HIV-1 is summarized in figure 1.4 below:  
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Figure 1.4: The viral life cycle of HIV. The virus binds to the CD4 receptor and to appropriate 
chemokine receptors resulting in the release of the viral core into the host cell cytoplasm. The viral RNA 
is converted into double stranded DNA and released into the nucleus where it is integrated into the host 
cell DNA. The DNA is transcribed to form viral proteins which are transported to the cellular membrane 
and assemble. The immature virus buds off the cell and mature proteins are produced (Sierra et al., 2005). 
Source: (Pomerantz and Horn, 2003). 
1.2. Antiretroviral therapy 
ARV therapy is used to suppress the replication of the HIV-1 virus by affecting the crucial steps 
involved in viral replication (Martinez-Cajas and Wainberg, 2008). The initial targets for ARV 
therapy are Protease (PR) and Reverse transcriptase (RT) due to their essential role in the HIV-1 
replication cycle (Shafer, 2002). To date, there are five classes of inhibitors: Reverse 
transcriptase Inhibitors (RTIs), Protease Inhibitors (PIs), Fusion Inhibitors, Integrase Inhibitors, 
and CCR5 receptor antagonistic (Imaz et al., 2011, Tang and Shafer, 2012). Both ARV 
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experienced and naïve patients are treated with the Nucleoside and Nucleotide Reverse 
transcriptase inhibitors (NRTIs), Non-Nucleoside reverse transcriptase inhibitors (NNRTIs) and 
Protease inhibitors (PIs) (Martinez-Cajas and Wainberg, 2008). The Fusion, integrase and entry 
inhibitors are restricted to ARV experienced patients with a history of treatment failures and who 
are facing ARV exhaustion and who need greater access to new classes of inhibitors (Imaz et al., 
2011, Martinez-Cajas and Wainberg, 2008). 
The use of a combination antiretroviral therapy (cART)  previously referred to as Highly Active 
Antiretroviral Therapy (HAART) has been considered the most successful therapy in 
maintaining long term suppression (Johnson et al., 2008). The combination is usually two NRTIs 
and one PI or NNRTI (Shafer, 2002). Ideally, these drugs should provide long term viral 
suppression in infected individuals, but this is unfortunately not always the case (Martinez-Cajas 
and Wainberg, 2008). The development of drug resistance has been an ongoing public health 
concern.  
1.2.1 Antiretroviral therapy in South Africa 
The main goal of ARV therapy is to reduce HIV related morbidity and mortality. According to 
the recent South African ARV treatment guidelines, the selection criteria for ARV therapy 
initiation in adults and adolescents include CD4 cell count ≤ 350 cells/mm3 irrespective of their 
WHO clinical stage, patients classified as WHO stage 3 or 4 irrespective of CD4 count, TB 
patients irrespective of CD4 count, as well as patients that require fast tracking, (i.e. starting 
treatment within 7 days of being eligible (Department of Health, 2013). The latter include HIV-1 
positive women who are pregnant or breast feeding or patients with a CD4 < 200 cells/mm3 or 
classified as WHO stage 4.  
The selection criteria for infants and children include: all children less than 5 years of age 
irrespective of their CD4 cell count as well children of 5 years to 15 years with WHO clinical 
stage 3 or CD4 ≤ 350 cells/mm3 are eligible to start ARV therapy.  In addition, children that 
require fast tracking are also eligible to start cART. These include children < 1 year of age, with 
a CD4 count <200 cells/mm3, or WHO clinical stage 4 or MDR, XDR-TB (Department of 
Health, 2013). The current recommended ART regimens for adults and adolescent as well as for 
infants and children are represented in table 1.1 and 1. 2. 
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Table 1.1: Standardized ART regimens for adults and adolescents 2013 (Department of 
health, 2013) 
                                                                       1st line  
All new patients needing treatment, including 
pregnant women 
TDF +FTC (or 3TC) + EFV 
FDC preferred 
Adolescents  ABC + 3TC+ EFV 
Contraindication to EFV TDF + (FTC or 3TC) + NVP  
Contraindication to TDF  AZT +3TC + EFV or (NVP) 
Contraindication to TDF and AZT  d4T + 3TC +EFV (or NVP) 
Contraindication to TDF, AZT, and d4T  ABC +3TC +EFV (or NVP) 
Currently on d4T- based regimen  TDF + FTC (or 3TC)  
FDC preferred  
 
                                                                     2nd line  
Failing on TDF-based 1st line regimen (patients 
with anemia and renal failure switch to ABC) 
AZT + 3TC +LPV/r 
Failing on d4T- based 1st line regimen  TDF + 3TC (or FTC) and LPV/r  
Dyslipidaemia or intractable diarrhea 
associated with LPV/r 
Switch LPV/r to ATV/r  
 
 
                                                                     3rd line  
Failing any 2nd line regimen  Specialist referral  
Patients failing on 2nd line therapy are managed 
by an expert panel and the 3rd line drugs are 
managed centrally 
Ratelgravir/Darunavir/ Etravirine adjusted 
according to genotype interpretation. 
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Table 1.2: Standardized ART regimens for infants and children 2013 (Department of 
health, 2013). 
                                                            1st line regimen  
All infants and children under 3 years (or < 10 
kg) 
ABC + 3TC +LPV/r 
Children ≥ 3 years (and ≥ 10kg) 
 
ABC+ 3TC +EFV 
Currently on d4T- based regimen  Changed d4T to ABC if viral load is 
undetectable.  If viral load > 1000 copies /ml 
manage as treatment failure   
 
                                                           2nd line regimen  
Failed 1st line PI- based regimen Recommended 2nd line regimen  
ABC + 3TC + LPV/r   
d4T + 3TC + LPV/r  Consult with expert for advise  
Unboosted PI-based regimen   
                                    Failed 1st line NNRTI based regimen  
Failed 1st line NNRTI –based regimen  Recommended 2nd line regimen  
ABC + 3TC +EFV (or NVP) AZT +3TC +LPV/r 
d4T + 3TC + EFV (or NVP) AZT + ABC +LPV/r  
 
                                                              3rd line regimens  
Failing any 2nd line regimen  Regimen based on genotype resistance testing, 
expert opinion and supervised care  
 
When patients are experiencing treatment failure, they are assed for virological, immunological 
and clinical failure before they change regimen. Virological failure is defined as an increase of 
HIV-1 viral load over 1000 copies/ml after initial virological suppression (HIV-1 viral load < 
400 copies/ml). Immunological failure is defined as decrease in CD4 count to 100 cell/mm2 after 
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six months of therapy or 50% decrease from the initial treatment peak CD4 count value 
(Schoffelen et al., 2013). Clinical failure is defined as the progression of disease with the 
development of opportunistic infections. Patients who are experiencing virological failure to 
their 1st line regimen regardless of good adherence are changed to the 2nd line regimen 
(Department of Health, 2004). Patients failing their 2nd line regimen are switch to a 3rd line 
regimen based on specialist recommendation (Department of Health, 2013). 
A new fixed-dose drug combination (FDC) was implemented in South Africa from the 1 April 
2013. The FDC is ―one ARV pill‖ consisting of: Tenofovir (TDF), Emtracibine (FTC) and 
Efavirenz (EFV). FDC is now used as the 1st line regimen, however at the moment, first priority 
is given to pregnant and breast feeding women. While the advantage of a FDC is that it will limit 
the problem of taking multiple pills and improve adherence, side effects continue to be a problem 
(Department of Health, 2013).  
1.3 HIV-1 drug resistance   
HIV-1 drug resistance results from the accumulation of mutations in the viral genes which are 
targeted by the drug (Charpentier et al., 2004). These mutations occur due to the high replication 
error rate of RT caused by the lack of a proof reading mechanism (3‘ to 5‘ exonuclease activity). 
Thus mutations can occur every time the virus replicates (estimated rate of 1×10-9 to 1×10-12 
mutations per cycle) resulting in a quasispecies of viral variants of related but distinctly different 
viruses (Abram et al., 2010, Halvas et al., 2010). Drug resistant variants emerge due to prolonged 
treatment and high viral fitness of the resistant variants over the wild type or by suboptimal 
treatment which allows continued replication of the virus. It can also be caused by transmission 
of resistant variants to treatment naïve patients (Martinez-Cajas and Wainberg, 2008). For most 
ARV drugs, resistance requires the presence of more than one mutation in the gene, and these 
mutations can occur continuously even if the patient is on therapy (Charpentier et al., 2004).  
The mutations that cause resistance to RTIs and PIs are classified as primary or secondary 
mutations. Primary mutations are single mutations and appear first. They results in low 
sensitivity to one or more inhibitors. Secondary mutations develop later and increase resistance 
and viral fitness when in combination with other mutations (i.e. they cannot cause resistance on 
their own) (Clavel and Mammano, 2010, Nyombi et al., 2008).   
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1.4 HIV-1 Reverse Transcriptase  
HIV-1 Reverse transcriptase (RT) enzyme is involved in RNA-dependent and DNA dependent 
DNA polymerization (Amiel et al., 2011, Shafer, 2002). The two main activities of the RT are 
polymerization and Ribonuclease activity (Singh et al., 2010). The structure of the HIV RT 
consists of two subunits: the p66 (p66 KDa) and p51 (p51 KDa) (figure 1.5). The p66 subunit is 
formed from the Gag-pol polyprotein as a result of protease excision between the PR and RT 
domain while the p51 is formed by protease excision of the C terminus of p66 (Sierra et al., 
2005).  Subunit p66 is made up of 560 amino acids and has the polymerase active site and the 
RNase H activity while p51 has 440 amino acids and has no enzyme activity (Shafer, 2002, 
Singh et al., 2010). The p66 subunit consists of three subdomains: the ―thumb‖, ―palm‖, and 
―fingers‖ (figure1.5). The ―palm‖ has the polymerase active site and close to the fingers domain 
is the RNase subdomain (figure 1.5).  The polymerase active site and the RNase activity are 
separated by the connection domain.  
                       
Figure 1.5: The crystal structure of HIV-1 RT illustrating the two subunits: p66 consisting of the palm 
(red), finger (blue) and the thumb (green) and p51 subunit (dark brown) derived from the RNaseH 
(orange). Source: (Singh et al., 2010).  
1.4.1 HIV-1 Reverse Transcriptase Inhibitors  
1.4.1.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
The RT inhibitors are classified into two classes: the nucleoside /nucleotide RT inhibitors 
(NRTIs) and the non-nucleoside RT inhibitors (NNRTIs). To date there are 7 NRTIs approved 
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by the US food and drug administration (FDA). This includes six  nucleoside inhibitors:  
Zidovudine (AZT), Lamivudine (3TC), Stavudine (d4T), emtracitabin (FTC), didanosine (ddi), 
abacavir (ABC) and  one nucleotide inhibitor tenofovir (TDF) (Tang and Shafer, 2012). The 
NRTIs are similar to nucleosides and they are activated by the host cellular enzymes to convert 
them their tri-phosphorylated form (Shafer, 2002). They therefore compete with the dNTPs and 
they are incorporated by the RT enzyme in the growing chain of the viral DNA causing chain 
termination because they lack a 3‘ hydroxyl group hence no additional nucleotide can be 
attached to them (figure1.6) (Clavel and Hance, 2004).  
1.1.4.2 Non -Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Currently there are four FDA approved NNRTIs including the Nevaripine (NVP), etavirenz 
(EFV), etravirine (ETV) and Delavirdine (DLV). However, DLV is rarely used due to complex 
dosing and limited clinical data (Tang and Shafer, 2012). The NNRTIs prevent HIV-1 replication 
by binding to the hydrophobic pocket in the RT enzyme, close to the active site. The inhibitor 
binding affects the flexibility of RT thereby preventing the synthesis of DNA (figure 1.6) 
(Shafer, 2002).  
  
Figure 1.6: Mechanism of action of NRTIs (a) and NNRTIs (b). (a) The NRTIs are similar to the 
dNTPs however they lack the 3‘ hydroxyl group. When they are incorporated by the RT enzyme in the 
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growing chain of the viral DNA, they cause chain termination and it production. (b) The NNRTIs directly 
binds to the RT, close to the active site and affects the flexibility of RT thereby preventing the synthesis 
of DNA. Source: (Pomerantz and Horn, 2003).  
1.4.1.1 Resistance to NRTIs  
There are two mechanisms that cause drug resistance to NRTIs (Shafer, 2002). One of the 
mechanisms is caused by mutations that prevent the NRTIs from being incorporated into the 
growing DNA chain during syntheses (Figure1.6a). The example of such mechanism is the high 
level of resistance to 3TC and FTC which is caused by mutation M184V/I (Singh et al., 2010). 
This mutation also confers resistance to Zalcitabine (ddC), ddi, ABC and has been described to 
decrease viral fitness (Singh et al., 2010, Tang and Shafer, 2012). Other examples of such 
mutations include the K65R, L74V and the Q151M complex. The mutation K65R causes 
resistance to TFV, ddi, ABC and to a lesser extent to 3TC and ddC (Singh et al., 2010). The 
mutation L74V causes resistance to ddC, ddi and ABC. The Q151M complex cause multidrug 
resistance to AZT, ddi, ddC, d4T and ABC (Singh et al., 2010).   
The other mechanism is caused by the nucleotide excision mutations (NEMs) that cause the 
removal of the NTRIs, allowing DNA synthesis to continue (figure 1.6b) (Shafer, 2002). The 
most common excising mutations are: M41L, D67N, K70R, L210W, T25N/F and K219Q/E 
(Singh et al., 2010). These mutations are also referred to as thymine analogue mutations (TAMs). 
TAMs are classified into two pathways referred to as type 1 and type 2 (Tang and Shafer, 2012). 
Type 1 includes mutations M41L, L20I and T215Y. These mutations emerge due to resistance to 
TDF, ABC, and ddi. Type II includes the D67N, K70R, T215F and K219Q/I/E. It has been 
reported that patients with many TAMs normally develop additional TAMs when receiving TDF, 
ABC and ddi instead of developing K65R or L74V which are the mutations associated with 
Tenofovir, abacavir and didanosine (Tang and Shafer, 2012). In addition, the presence of M184V 
together with the TAMs has been reported to be the most common pattern that causes resistance 
to all NRTIs (Tang and Shafer, 2012).  
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Figure 1.7: The two mechanism of resistance to NRTIs. (a) The incorporation of the nucleoside 
analogue into drug sensitive virus causes viral DNA termination. The mutations in the drug resistant 
viruses prevent the incorporation of the nucleoside analogue into the growing viral DNA. (b) ATP is 
prevented from binding to the RT that has formed a complex with a nucleoside analogue in the drug 
sensitive virus. The mutations that cause resistance to nucleoside analogues, i.e. TAMs, allow ATP to 
bind to the RT near the 3 ‗end of the viral DNA which has been terminated by the incorporation of a 
nucleoside analogue. ATP then excises the analogue, allowing reverse transcription to continue. Source: 
(Clavel and Hance, 2004).   
1.4.1.2 Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors 
The mutations that result in NNRTI resistance are located in the hydrophobic pocket which 
blocks the NNRTIs from entering the binding pocket (Figure1.8). These mutations can result in 
high level resistance to one or more NNRTIs (Shafer, 2002). NNRTI resistance usually develops 
when the NNRTIs are used in the presence of incomplete suppression of viral replication 
suggesting that resistance may be due to preexisting mutants (Shafer, 2002). The commonly 
described NNRTI mutations include L100I, K103N, V106A, Y181C, Y188C/L and G190A 
(Singh et al., 2010, Tang and Shafer, 2012). Mutations K103N/S and V106M are the most 
common NNRTI mutations and they develop due to resistance to etravirine (ETV), and or 
rilpivirine (RVP) (Tang and Shafer, 2012). Mutation E138K is the recently discovered mutation 
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that develops in patients experiencing virological failure to RVP. However E138K also cause 
resistance to ETR, efavirenz (EFV) and nevaripine (NVP).  
                                             
Figure 1.8: The mechanism of resistance to NNRTIs. In the drug sensitive viruses, NNRTIs binds to 
the pocket next to the active site of the RT and prevents polymerization of DNA by the RT. In drug 
resistance viruses, mutations block the binding of the NNRTIs, allowing DNA polymerization to 
continue. Source: (Clavel and Hance, 2004).              
1.5 HIV-1 Protease  
HIV-1 protease is a homodimeric aspartyl enzyme consisting of two monomers, each  99 amino 
acids long (Martinez-Cajas and Wainberg, 2008). The PR consists of three domains: the active 
site, the dimerization and the flap domain (Figure1.9). The active site confers the hydrophilic 
activity of the enzyme while the flap domain allows the entry of the large-gag poly proteins. The 
dimerization domain is responsible for dimer formation as well as stabilization of an active PR 
(Martinez-Cajas and Wainberg, 2008). 
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Figure1.9: The crystal structure of the HIV-1 PR. Inhibitors fit inside the active site cavity. The flaps 
are flexible structures that allow the entry of the large-gag poly proteins. The aspartates (ASP 25) allow 
hydrolytic activity of the enzyme. Source: (Martinez-Cajas and Wainberg, 2008). 
The PR enzyme is responsible for the formation of enzymes and proteins of the virus through the 
process of post translational processing of the viral Gag and Gag-pol (Clavel and Mammano, 
2010). The PR cleaves Gag into p17 matrix (MA), p24 capsid (CA), p2 (SP1), p7 nucleocapsid 
(NC) and p6 gag. The Gag–pol polyprotein is cleaved into p17 (MA), p24 (CA), p2 (SP1), p7 
(NC), Transframe protein (TFP), p6 pol, Protease (PR), reverse transcriptase (RT), integrase (IN) 
and RT-RNase H (Ghosn et al., 2011, Larrouy et al., 2010) Figure 1.10. 
 
Dimerization Domain 
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Figure 1.10:  Diagram illustrating gag and gag pol processing sites. The Gag is cleaved into 5 sites 
(MA, p24 capsid /CA, p2 /SP1, p7/NC and p6 gag) while Gag-pol is cleaved into 6 sites (p7 /NC, TFP, 
p6pol, PR, RT, IN) and single site Nef. Source: (de Oliveira et al., 2003).   
1.5.1 HIV-1 Protease Inhibitors 
PIs are similar in the structure to the PR substrate, thus competing with it for binding to the PR 
enzyme active site (Shafer, 2002). They therefore inhibit the protease enzyme function and the 
formation of the viral proteins (Figure1.10) (Clavel and Mammano, 2010, Shafer, 2002).  
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Figure 1.11: Mechanism of action Protease inhibitors (PIs). The protease inhibitor targets the protease 
enzyme by preventing the cleavage of the polypeptide and maturation of the virion. Source: (Richman, 
2001).    
To date there are nine FDA approved PIs: Saquinavir (SQV), Indinavir (IDV), Ritonavir (RTV), 
Nelfinar (NFV), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Tipranovir (TPV) and 
Darunavir (DRV). These PIs are essential components of HAART due to their potency compared 
to the other ARVs (Ali et al., 2010). All of these PIs are boosted with RTV which is used to 
inhibit cytochrome P450 (cyp) 3A, except for NFV which has low antiviral efficacy (Tang and 
Shafer, 2012).  
1.5.2 Resistance to Protease Inhibitors  
Resistance to the PIs is caused by mutations in the substrate cleft which decreases the binding 
between mutant protease and the inhibitor. The development of PI resistance is generally a 
gradual process and the increase level of resistance requires the presence of many mutations in 
the gene itself (Charpentier et al., 2004, Shafer, 2002). 
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The primary mutations occur at the amino acids which are found inside the substrate cavity, 
thereby causing resistance by decreasing the binding affinity between the inhibitor and the 
mutant PR enzyme. The secondary mutations occur at amino acids which are found outside the 
substrate cavity, and can either compensate for the mutations found at the active site or decrease 
activity of the mutant protease (Amiel et al., 2011, Clavel and Hance, 2004, Shafer, 2002). The 
most characterized PI mutation that has been observed in patients who have developed resistance 
to various PIs is V82A (Clavel and Mammano, 2010). The other mutations include the D30N, 
V32I, M46I/L, G48V/M, I50V/L, I54V/T/J/M, L76V, I84V, N88S and L90M (Tang and Shafer, 
2012). All these mutations cause resistance to one or more PIs except for D30N, and I50L which 
cause resistance to NFV and ATV. Most of these mutations decrease the replication capacity of 
the virus as the processing of the natural substrate (Gag) is decreased (Dam et al., 2009). 
However, drug resistance to PIs doesn‘t develop at the PR gene only but also in protease 
cleavage sites consisting of Gag and gag- pol polyproteins (Clavel and Mammano, 2010).  
1.5.3 The Contribution of Gag Mutations to Protease Inhibitor Resistance 
The process of post translational processing of the viral gag polyprotein is a crucial step in HIV 
viral replication (Clavel and Mammano, 2010). The gag polyprotein is the main substrate of PR 
and it has been shown that mutations which are located in the NC/SP2/p6 gag region play a role 
in the development of PI resistance (Clavel and Mammano, 2010, Dam et al., 2009). However, 
these gag cleavage site mutations also compensate for the viral fitness loss by facilitating the 
mutated PR to cleave the gag substrate (Clavel and Mammano, 2010, Dam et al., 2009, Kozisek 
et al., 2012).  
In the study by Dam et al., 2009, the mutations that they observed to contribute to the evolution 
of PI resistance were, I437V and P453L at sites NC/SP and SP2/p6 respectively. In another study 
by Clavel and Mammano 2010, they showed that mutations L449F at P1 of the SP2/p6 cleavage 
site, Q430R at P3‘ and A431V at P2 (NC/SP2) also contributed to the evolution of PI resistance. 
They also indicated that there was a correlation between the mutations at the PR and those at the 
gag region. The gag mutations A431V and I437V were associated with PI mutations V82A 
and/or M46I and gag mutation L449F associated with I84V (Clavel and Mammano, 2010). 
However, some of the gag mutations occur even when the PR mutations are not observed (Ghosn 
et al., 2011, Nijhuis et al., 2007). In a study by Nijhuis et al 2007, they showed that NC/P1 
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cleavage site mutation K436E and or I437T/V were present in all the resistance viruses without 
PR mutations. However, when these mutations were introduced into the wild type they caused PI 
resistance in all the viruses that had no primary mutations. This indicates that HIV-1 can cause 
resistance to PIs by changing the PR substrate instead of the PR itself (Nijhuis et al., 2007).  
1.6 Drug Resistance Testing 
The goal of drug resistance testing is to provide information to help with the selection of 
effective ARV more likely to attain and maintain viral suppression (Paredes i Deiros, 2009). 
There are two types of resistance methods i.e. genotypic and phenotypic methods (Hirsch et al., 
2008). 
1.6.1 Genotypic methods 
Genotypic resistance methods detect the presence of drug resistance mutations in the viral 
enzymes (PR, RT and IN) which are targeted by the ARV drug.  The standard approach of 
genotypic methods involves amplifying specific regions of the HIV-1 genome, followed by 
direct sequencing of the amplified products by Sanger sequencing (Tang and Shafer, 2012). 
There are two ways in which genotypic testing can be performed: ―in-house‖ genotypic testing or 
using commercial kits (Paredes i Deiros, 2009).  
The commercial kits include the TruGene HIV genotyping system assay (Siemens USA), Celera 
ViroSeq HIV-1 Genotyping system and the GeneSeq HIV (Monogram Biosciences) (Paredes i 
Deiros, 2009, Tang and Shafer, 2012). ―In-house‖ resistance genotyping is much cheaper than 
commercial kits. However, in-house testing is not standardized and inter-subject variability is 
likely to happen (Paredes i Deiros, 2009). 
In clinical practice,  the genotypic methods are more commonly used than the phenotypic 
methods because they are much cheaper, have less turnaround time and they have the ability to 
detect mutations occurring in mixtures which cannot be done by phenotypic methods 
(Charpentier et al., 2004, Shafer, 2002, Tang and Shafer, 2012). However, standard genotyping 
detects mutations in the major (dominant) viral population, but is incapable of detecting minority 
mutations (Gianella and Richman, 2010).  
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1.6.2 Phenotypic methods 
Phenotypic methods involve the direct measure of mutations contained in the virus on drug 
susceptibility (Gianella and Richman, 2010). Therefore, the results of drug susceptibility are 
reported as the level of fold change in susceptibility of the investigated virus compared with a 
control virus (Tang and Shafer, 2012). 
There are two phenotypic methods that are commercially available i.e. the Phenosense 
(Monogram Biosciences) and Antivirogram (Virco) (Tang and Shafer, 2012). The Phenosense 
assay is more sensitive and reproducible than the Antivirogram assay. However phenotypic 
methods are expensive and time consuming compared to genotyping methods.  
Again, the phenotypic methods also only detected mutations in the major viral population while 
the detection of minority variants is limited (Gianella and Richman, 2010, Halvas et al., 2010, 
Metzner et al., 2005). 
1.6.3 Testing for minority variants 
As minority variants cannot be detected and quantified by standard genotyping, more sensitive 
methods have been developed to detect minority variants. This includes the standard cloning, 
Single Genome Sequencing (SGS), Allele Specific PCR (ASPCR) and the Ultra Deep Pyro-
Sequencing (UDPS) (Halvas et al., 2010, Paredes i Deiros, 2009). Table 1.3 summarizes the 
principles of these techniques.  
1.6.3.1 Standard cloning and sequencing of multiple clones  
Cloning of viral fragments has been widely used to study viral populations, mainly in assessing 
the virus diversity and detection of HIV-1 drug resistance mutations (Eshleman et al., 2003, 
Ramirez et al., 2013). It allows the analysis of genetic linkage of each detected mutation. 
However, the sensitivity of this method depends on the number of colonies that are analyzed. 
Paredes i Derios, 2009 reported that in order to detect minority variants present in 10% of the 
viral population, at least 30 colonies per sample should be analyzed. Although this method is 
easy compared to the other methods, it is very time consuming and labor intensive and relatively 
costly (Liang et al., 2011, Ramirez et al., 2013). Additionally, polymerase induce sequencing 
errors can complicate the results when sequencing cloned PCR products (Liang et al., 2011).  
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1.6.3.2 Single genome sequencing 
Single genome sequencing (SGS) was developed by Palmer and colleagues (Palmer et al., 2005), 
based on previous limiting dilution assays (Brown and Cleland, 1996, Holmes et al., 1992, 
Simmonds et al., 1990, Zhang et al., 1991). This method allows a more refined analysis of the 
whole gene with the sequencing of the single virus particles obtained from the original HIV-1 
particle, allowing the analysis of genetic linkage of each detected mutation. In this method, the 
number of DNA sequences that can be analyzed per samples is generally 20 to 40 single virus 
particles per sample, although the number can be increased (Palmer et al., 2005). The sensitivity 
of SGS in detecting minority variants can be as low to 2% of the viral population (Table1.3), 
however this method is expensive, time and labor consuming (Paredes i Deiros, 2009).  
1.6.3.3 Allele Specific PCR 
Allele specific PCR (ASPCR) is the most sensitive method in detecting minority variants 
(Paredes i Deiros, 2009). It can detect minority variants to as low as 0.003-0.4 % of the viral 
population (Table1.2). It is less labour intensive, cheap and less time consuming than SGS or 
clonal sequencing (Paredes i Deiros, 2009). However, ASPCR is very specific and sensitive in 
detecting minority variants, as it does not give information on other drug resistance mutations 
present in the virus (Gianella and Richman, 2010). In addition, with ASPCR it is difficult to 
establish a clinically relevant threshold for minority variant, due to a loss of linearity in the 
measuring of normal proportions below 0.10-1% (Paredes i Deiros, 2009). However, ASPCR 
continues to be an important and affordable method to detect minority variants (Paredes i Deiros, 
2009). 1.6.3.4 Ultra deep Pyro- Sequencing  
Ultra deep Pyro- Sequencing (UDPS) was developed by researchers at life 454 sciences Roche 
Co (Brandford, CT, USA) (Margulies et al., 2005). This method uses emulsion PCR together 
with massive parallel pyrosequencing technique where many sequences of individual molecules 
generated from RT PCR products are sequenced in a single run (Simen et al., 2009). This type of 
technology results in huge number of sequence, allowing the detection of multiple drug 
resistance mutation.  The sensitivity to detect minority variants depends on the coverage and 
depth attained i.e. the average number of times a gene has been sequenced during a run. In 
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addition, its sensitivity to detect minority variants can be as low as 0.5- 1% in viral population 
(Paredes i Deiros, 2009). 
UDPS also allows for sequencing of the individual template and can determine the genetic 
linkage within the same viral genome in the same way as cloning and SGS (Gianella and 
Richman, 2010). In additions, UDPS is simpler and less time consuming. Although UDPS 
remains one of the most sensitive methods, it is more expensive and generates a lot of data that 
requires extensive bioinformatics expertise in order to fully analyze the data (Paredes i Deiros, 
2009, Ramirez et al., 2013). 
Table 1.3: Summary of commonly used techniques to detect HIV-1 minority variants 
(Paredes i Deiros, 2009).  
 Standard Cloning Single Genome 
sequencing  
(SGS) 














mutants vs WT in 






Sensitivity > 10 % 2% 0.003- 0.4% 0.5 % 
# mutations Multiple Multiple 1 300-400bp 
Linked mutations Yes Yes No Yes 
Labor intensity ↑↑↑ ↑↑↑↑↑ ↑↑ ↑ 
Cost ↑ ↑↑↑↑ ↑↑ ↑↑↑↑↑↑ 
Best Experience,  PPV Enables linkage of 
mutations 




Rapidity of results 
Worst S,  NPV Only 1 mutant, SP, 
effect of 
polymorphism 
Cost,  labor 
intensity, 
Short sequence , 
background noise, 
SP 
S: sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: negative positive value. 
(Paredes i Deiros, 2009). 
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1.7. Minority drug resistance mutations 
HIV-1 has a high replication rate and errors are likely to happen. The reverse transcriptase 
enzyme involved in the replication of RNA viruses has a high error rate due to the lack of a proof 
reading mechanism (3‘ to 5‘ exonuclease activity). Thus mutations can occur every time the 
virus replicates (estimate rate of 1×10-9 to 1×10-12 mutations per cycle) resulting in a 
quasispecies of viral variants of related but distinctly different viruses (Abram et al., 2010, 
Halvas et al., 2010). A small proportion of these variants (minority variants) could harbor 
mutations related to drug resistance.  
Minority variants are important as they impact on ARV therapy and some studies have found 
that these minority mutations can later emerge as the major viral population (Metzner et al., 
2005). This can be either because they have developed more resistance mutations, or can be due 
to partially suppressive ARV therapy, allowing the minority population to have a higher growth 
advantage over the majority population (Charpentier et al., 2004). Many studies have shown that 
minority drug resistance mutations can exits both in treatment naïve and treatment experience 
patients (Gianella and Richman, 2010). But as expected, these minority mutations are more 
frequently detected in treatment experience patients and may be the cause of virological failure 
(Gianella and Richman, 2010).  
In a study by Metzner et al., 2005, quantitative real time PCR was used to detect minority 
variants using allele discriminator oligonucleotides which were specific for the L90M resistance 
mutation in PR and K103N and M184V mutations in RT. In five of the ten patients with 
detectable drug resistance, the detected mutations represented a minor viral population and were 
not detected by standard genotyping. This suggested that minor HIV-1 drug resistance mutations 
are underrated when detected only by standard genotyping methods (Metzner et al., 2005).    
Roquebert et al., 2006 also did a study on minority variants where they investigated the role of 
PR and gag cleavage sites in patients failing a PI-inclusive regimen. No PI or gag mutations were 
detected using standard genotyping before virological failure, however, the D30N and N88D 
mutations were detected in some of the patients investigated after virological failure. The 
protease and gag regions were cloned and analyzed. After virological failure, PI minority 
variants (M46I and L90M) were present among clones which had mutations D30N and N88D. 
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Gag mutations L449P, S451N and P453L were also present in clones with PI mutations D30N 
and N88D (Roquebert et al., 2006a). This suggested that HIV can use other mechanisms to cause 
resistance to PIs by affecting the gag and thus these mutations could compensate for PI 
resistance (Nijhuis et al., 2007, Roquebert et al., 2006b). 
1.8 HIV analysis using online tools  
1.8.1 Stanford University HIV Drug Resistance Database (HIVdb)  
The Stanford University HIVdb which is also called the HIV RT and PR sequence database is an 
online database that is used for drug resistance interpretation. It consists of PR and RT sequences 
from published data on: 1) genotype-treatment correlation, 2) genotype- phenotype correlation 
and 3) Genotype-outcome correlations (Shafer, 2006). HIVdb aligns the submitted RT and PR 
sequence and compares it to the subtype B reference strain (HXB2) (Tang and Shafer, 2012). 
The programme generates a list of drug associated mutations where mutations are assigned drug 
penalty scores based genotypic-phenotypic correlative data. The programme also gives the level 
of susceptibility to ARV drugs as well as comments about the ARV resistance mutations found 
(Shafer, 2002, Tang and Shafer, 2012).  
1.8.2 RegaDB sequence analysis tools 
RegaDB is a database with software tools, including a sequence analysis tool which is used for 
drug resistance interpretation (http://jose.med.kuleuven.be/sequencetools). The sequence analysis 
tool performs a codon-corrected alignment, corrects detected frameshifts and translates the 
sequences into its 3 open reading frame (ORF). It also performs a Needleman-Wunsch amino 
acid alignment which calculates the alignment scores. The output of the RegaDB shows the 
number of short sequences, scores, corrected frameshifts as well as the failed sequences. Finally, 
it gives a list of tables in XML format showing the amino acids, nucleotides, amino acids 
mutations and the diagnostic mutations list.  
1.8.4 HyPhy package in Datamonkey 
Hypothesis testing using phylogenies (HyPhy) is a software package in Datamonkey that 
performs likelihood based analysis to study the pattern of sequence evolution (Delport et al., 
2010, Kosakovsky Pond and Frost, 2005). One of the standard analyses methods found in the 
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HyPhy package is the Positive selection analysis. HyPhy uses 4 approaches to determine sites 
under Positive selections. This includes the single likelihood ancestor counting (SLAC), fixed 
effect likelihood (FEL), internal branch FEL (IFEL) and a random effect likelihood (REL) 
(Delport et al., 2010, Kosakovsky Pond and Frost, 2005). These methods estimates the rate of 
nonsynonymous (dn) and synonymous (ds) changes occurring at each site in the sequence to 
identify sites under positive or negative selection (Kosakovsky Pond and Frost, 2005).  
SLAC is the most conventional counting method that involves reconstruction of the ancestral 
sequences using a single most likely ancestral reconstruction that considers all possible ancestral 
reconstructions or sampling from ancestral reconstructions (Kosakovsky Pond and Frost, 2005). 
The FEL method estimates the substitution rate of nonsynonymous and synonymous at each site 
of the branch while the IFEL determine the selection pressure that occurs on the internal 
branches of a tree (Kosakovsky Pond and Frost, 2005). Generally, the FEL and IFEL are the best 
methods in terms of statistical performance and computational expense. The REL is an extensive 
codon- based selection analysis that allows nonsynonymous and synonymous rate of variation 
with the selection pressure at an individual site (Kosakovsky Pond and Frost, 2005). 
1.9. An overview of Phylogenetic analysis  
Phylogenetic is the scientific study which estimates the evolutionary relationships between 
groups (e.g. sequences) based on the comparison of amino acids or nucleotides. To represent this 
relationship, a phylogenetic tree is constructed. A phylogenetic tree is composed of branches 
(edges) and nodes (figure 1.12). Branches connect the nodes which are the points at which two or 
more branches diverge. Both the branches and the nodes can be either internal or external. An 
internal node (hypothetical ancestor) represents everything arising from it while the external 
nodes (leaf) represent the taxa also called the Operational taxa units (OTUs) (Baldauf, 2003). In 
addition, phylogenetic trees are drawn with proportional branch lengths whereby the branch 
length corresponds to the amount of evolution. Thus the longer the branch length the more 
diversity in the sequence compared to the others (Baldauf, 2003). 
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Figure 1.12: Example of a phylogenetic tree. A-E represents external nodes while F-I represent internal 
nodes (ancestral unit). Clade represents a group of taxa that share a common ancestor  (Freed, 2001). 
Phylogenetic trees can be rooted or unrooted (Figure 1.13). Rooted trees have a root that 
indicates common ancestor of all the OTUs thus illustrating the direction of evolutionary process 
while the unrooted only positions the taxa relative to each other without showing the direction of 
evolutionary process (Baldauf, 2003, Rizzo and Rouchka, 2007).   
 
Figure 1.13: (a) Example of a rooted tree and (b) of unrooted tree. Source: (Salemi et al., 2009) 
1.9.1 Methods for estimating phylogenetic trees 
1.9.1.1 Neighbor joining method 
The neighbor joining (NJ) method is the distance method that uses the genetic distance between 
sequences to construct a phylogenetic tree (Bos and Posada, 2005). This is based on the 
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hypothesis that the difference between two sequences is directly related to their phylogenetic 
relationship (San Mauro and Agorreta, 2010). The difference between the sequences is due to a 
number of changes that have occurred along the branches, that is evolutionary distance (San 
Mauro and Agorreta, 2010). The genetic distance can also be the differences between the pair of 
sequences based on the transition (purines to purines or pyrimidines to pyrimidines) and 
transversion (pyrimidine to purines) substitution rate (figure 1.14) (Bos and Posada, 2005). An 
example of a distance measure is the Kimura‘s 2-parameter model, which is also a substitution 
model. The distance methods are relatively quicker compared to the other methods. However, 
they don‘t give information about the sequences as they are distance based (San Mauro and 
Agorreta, 2010).  
                                                             
Figure 1.14: A substitution matrix illustrating the two possible different rates of transitions (A-G, C-T) 
and four possible transversion (A-T, A-C, C-G, and G-T). In this substitution matrix, substitution 
parameters are reversible, so that the rate of change from nucleotide I to nucleotide j is the same as rate of 
change from j to I (Bos and Posada, 2005).  
1.9.1.2. Maximum likelihood methods 
Maximum likelihood (ML) uses the sequence data directly to select the tree that best explains the 
data based on the specific substitution model (Bos and Posada, 2005). The likelihood of a tree is 
the probability of observing the data provided with the tree and the model of evolution (San 
Mauro and Agorreta, 2010). The likelihood can thus be estimated for different substitution 
models and the ML found. The ML has more statistical power in comparison to genetic distance 
methods, therefore allowing a robust way of estimating phylogenies and understanding sequence 
evolution (Bos and Posada, 2005, San Mauro and Agorreta, 2010). However, ML methods are 
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more computational intensive especially when there are large numbers of sequences to be 
analyzed (Bos and Posada, 2005). 
1.10. Nucleotide substitution model  
A nucleotide substitution model provides an outline whereby the phylogenetic construction 
method estimates the parameters used to find the best fit tree. The models differ according to the 
number of parameters used to represent evolutionary change. Model parameters can represent 
differences in nucleotide frequencies, substitution rate (figure 1.14) and among site variation. 
Some of these parameters have been combined, resulting  in other models which share some of 
the parameters (Bos and Posada, 2005). The most commonly used nucleotide substitution models 
include: the Jukes and Cantor model (JC69), Felsenstein (F81), Kimura 2-parameter (K2P), K80, 
K81, Hasagawa, Kishino and Yano (HKY85), symmetrical model (SYM), transition model 
(TIM), transversion model (TVM) and general time reversible (GTR) (Bos and Posada, 2005, 
Posada and Crandall, 1998). 
The JC69 is the simplest model and it considers that all nucleotides substitution have an equal 
probability. The F81 method determines the probability of nucleotide change using the 
equilibrium nucleotide frequencies. The K2P uses a substitution matrix that allows for transition 
and transversion rates (figure 1.14). The K80 model is similar to the K2P, while K81 is similar 
K3P. The HKY85 allows for different rates in nucleotide pairs i.e. transversion/transition. The 
GTR has other models nested within it. It allows six substitution rates to have different rates and 
also allows for different nucleotide substitutions (Gatto et al., 2006, Lio and Goldman, 1998).  
1.11 Model selection  
The most commonly used methods for selecting the appropriate model includes the Likelihood 
ratio test (LTR) and the Akaike Information Criterion (AIC) (Bos and Posada, 2005, Posada and 
Crandall, 1998). These methods provide rigorous statistical support to select and justify the 
appropriate model (Bos and Posada, 2005). The LRT is calculated by comparing the likelihood 
scores of the null model (L0) i.e. the simple model and the alternative model (L1) that is the more 
complex and parameter rich model (Posada and Crandall, 1998). The significance of the LTR is 
also determined.  
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The AIC calculates the likelihood of the models and gives a score based on the number of model 
parameters (Bos and Posada, 2005, Posada and Crandall, 1998). The appropriate model is given 
to the one with the smaller AIC value. The AIC has an important advantage over LRT by 
comparing all the models, instead of performing sequential pairwise comparison (Bos and 
Posada, 2005). 
1.12 MODELTEST 
To test the model of DNA substitution, a MODELTEST is performed. This programme 
compares the different DNA substitution models using a hierarchical hypothesis testing 
framework (Posada and Crandall, 1998). The programme calculates the LTR statistics and its 
associated P-values as well as the AIC values (Posada and Crandall, 1998). MODELTEST is 
performed in a phylogenetic package called PAUP* (Phylogenetic Analysis Using Parsimony). 
Initially, a file called modelblockPAUPb10.txt is added to the end of the sequence alignment file. 
This file contains a matrix of log likelihood scores resulting from the execution of a block of 
PAUP* (Posada and Crandall, 1998). PAUP* then tests the sequence alignment against the 56 
models of evolution and gives an output called model. Scores. MODELTEST is then executed to 
find the best model. The MODELTEST output includes the P-values related to the test 
performed and the P-values are interpreted and the best model selected (Posada and Crandall, 
1998). 
1.13 Aims and objectives of the study 
To determine the minority drug resistant variants that were not detected by population 
sequencing in patients failing HAART 
Objectives: 
• To clone PCR products that were previously genotyped from patients failing HAART. 
• To sequence the clones to detect the minority mutations.  
• To perform Ultra Deep Pyrosequencing (UDPS) on selected patients. 
• To compare the minority mutations detected in cloning vs UDS. 
• To amplify the gag region in these patients. 
• To correlate mutations in gag and protease. 
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2.1. Introduction 
The goal of genotyping resistance testing is to assist physicians /healthcare provider to monitor 
the patients‘ response to ARV therapy and make choices of successful ARV treatment for 
patients with a resistant virus (Martinez-Cajas and Wainberg, 2008, Shafer, 2009). The 
genotyping method that has been routinely used is the standard genotyping (population 
sequencing) which involves RNA extraction, reverse transcription, PCR amplification and the 
direct sequencing of the PCR products  using the Sanger sequencing approach (Shafer, 2009). 
As HIV-1 has a high replication error rate due to the lack of a proof reading mechanism of the 
reverse transcriptase enzyme, mutations can occur every time the virus replicates resulting in a 
quasispecies of viral variants of related but distinctly different viruses (Abram et al., 2010, 
Halvas et al., 2010). A small proportion of these variants (minority variants) could harbor 
mutations related to drug resistance. Therefore this complicates the analysis of standard 
genotyping results as these method only detects mutations >20% of the HIV-1 population but not 
the minority variants which occur at low levels in the HIV-1 population (Johnson and Geretti, 
2010). Thus more sensitive methods such as the cloning and sequencing of multiple clones, 
Allele Specific PCR (AS-PCR), Single Genome Sequencing (SGS) and Ultra-Deep 
Pyrosequencing (UDPS) have been used to detect the minority variants (Gianella and Richman, 
2010, Halvas et al., 2010). In this study, PCR products that were previously genotyped were 
cloned and multiple clones were sequenced using the Sanger sequencing method. In addition,   
UDPS was performed to compare minority variants detected by cloning and UDPS. This is an 
important study as the impact of minority variants related to drug resistance on clinical outcomes 
remains unclear although there is evidence that these variants can influence treatment efficacy. 
2.2. Materials and methods 
2.2.1 Study design  
This is a retrospective study and this study was approved by the Biomedical Research Ethics 
Committee of the University of KwaZulu Natal (REF: BE191/12).  
Stored plasma samples were obtained from patients failing HAART. These patients were 
enrolled in the study title: Molecular characterized of HIV-1 protease cleavage steps in South 
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African patients failing HAART-viral fitness and drug resistance in HIV-1 subtype C. Ethical 
approval for the study was obtained by the Biomedical Research Ethics Committee of the 
University of KwaZulu Natal (BREC reference: BF 068/08) as well as McCords Hospital 
Research ethics committee numbers 2305086/6.1 mg and 280907/4.2 mt. 
2.2.2. Study Participants 
Six of the stored samples in the study had genotypic data from earlier time points. The samples 
were genotyped at two time points. They were separated into those who were genotyped at 1st 
line failure which include (2 NRTIs and 1 NRTI), (1st time point) as well as at 2nd line failure (2 
NRTIs and PI) (2nd time point) and those that were genotyped at 2nd line failure only (both time 
points). The 1st group was studied to investigate the resistance profile before and after starting a 
PI inclusive regimen while the 2nd group was studied to investigate the resistance profile with 
prolonged PI therapy. The overview of the study participants is represented in the figure below: 
 
Figure 2.1: Diagram showing the overview of the study participants. 
2.2.3. Patients characteristics 
2.2.3.1 Characteristic of patients that were switched from 1st to 2nd line therapy. 
The 1st line treatment for PCSM004 included D4T, 3TC and EFV from April 2005 before 
replacing EFV with NVP in October 2007. In July 2008 a 1st genotype was performed and the 
viral load was 620 cpm while the CD4 cell count was 270 cells/ml. In September 2008, the 
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patient was then changed to 2nd line treatment (AZT, DDI and Kaletra). The viral load had 
increased to 7200 cpm while the CD4 cell count decreased to112 cells/ml. In April 2009, a 2nd 
genotype was performed.  
The 1st line treatment for PCSM009 also included D4T, 3TC and EFV from September 2005 to 
June 2008. The patient was then change to 2nd line treatment (AZT, DDI and Kaletra). The 1st 
genotype was performed in July 2008. The viral load was 4100 cpm while the CD4 cell count 
was 204 cells/ml. In July 2009, a 2nd genotype was performed and during this time, the viral 
loads had increased to 8300 cpm while the CD4 cell count decreased to167 cells/ml.  
The 1st line treatment for PCSM012 also included D4T, 3TC and EFV from February 2007 to 
September 2008. The patient was then changed to 2nd line treatment (AZT, 3TC and Kaletra). In 
November 2008, a 1st genotype was performed and the viral load was 3700 cpm while the CD4 
cell count was 721 cells/ml. In July 2009, a 2nd genotype was performed. During this time, the 
viral load had increase to 13000 cpm while the CD4 cell count decreased to 82 cells/ml. The 
summary of these patients‘ characteristics is represented in the table below: 
Table 2.1: Characteristics of patients that were switched from 1st to 2nd line therapy.  
 1st time point 2nd time point 


















n/a n/a D4T, 3TC, 
EFV 
04/05-10/07 112 72000 AZT, DDI, 
Kaletra 
09/08-04/09 
 270 620 D4T, 3TC, 
NVP 
10/07-09/08     
PCSM009  204 4100 D4T,3TC, 
EFV 
09/05- 6/08 167 83000 AZT, DDI, 
Kaletra 
6/08-06/09 
PCSM012 721 3700 D4T,3TC, 
EFV 
02/07-09/08 82 130000 AZT, 3TC, 
Kaletra 
09/08-7/09 
*CD4 counts and VLs are at the time of genotyping. 
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2.2.3.2 Characteristic of patients that remained on 2nd line therapy in both time points  
The 2nd line treatment for PCSM001 included DDI, AZT and Kaletra from December 2006 
before replacing AZT with 3TC in January 2008. In March 2009, the 1st genotyped was 
performed and during this time point the viral load was 3200 cpm and the CD4 cell count 280 
cells/ml. In April 2009, a 2nd genotype was performed and at this time point the viral load had 
increase to 21000 cpm while the CD4 cell count also increased to 388 cells/ml. 
The 2nd line treatment for PCSM002 included D4T, 3TC and Kaletra from March 2008 to April 
2009 before replacing D4T and 3TC with AZT and DDI to June 2009. In February 2009, a 1st 
genotype was performed and the viral load was 84000 cpm and the CD4 cell count was 1562 
cells/ml. In April 2009, a 2nd genotype was performed. During this time point, the viral load had 
decrease to 8000 cpm while the CD4 cell count increased to 1967cells/ml.  
Patient PCSM007 has been on 1st line treatment D4T, 3TC and EFV from March 2007 before 
replacing D4T with AZT in March 2008. The patient was then changed to 2nd line treatment EFV 
and Kaletra. In March 2009, a 1st genotyped was performed and the viral load was 7900 cpm 
while the CD4 cell was 480 cells/ml. The 2nd genotype was performed in May 2009. During this 
time point the viral load increased to 61000 cpm while the CD4 cell count decrease to 179 
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Table 2.2: Characteristic prior the 1st genotype and the 2nd genotype of patients that 
remained on 2nd line therapy. 
 1
st
 time point 2
nd
 time point 





Treatment Time on 
treatment (prior 






Treatment  Time on 
treatment  
   AZT, DDI, 
Kaletra 
12/06- 03/09     
PCSM001  280  3200 DDI, 3TC, 
Kaletra 
01/08-03/09 388 21000 DDI, 3TC, 
Kaletra 
03/09-04/09 
PCSM002  1562 84000 D4T,3TC, 
Kaletra 
02/08- 03/09 1967 8000 AZT,DDI, 
Kaletra 
03/09-05/09 
   D4T,3TC, 
EFV 
03/07-03/08     
PCSM007 480 7900 AZT, 3TC, 
EFV 




2.2.4 Generation of PCR products by In-house resistance genotyping assay  
PCR products were generated using an in-house resistance genotyping assay. Briefly, Viral RNA 
was extracted from plasma using the QIAamp Viral RNA Mini Kit (QIAGEN, Germany) 
according to the manufacturer‘s protocol. RNA was reverse transcribed to cDNA with Supercript 
III and amplification was done with primers as previously described in Jennifer Giandhari thesis 
(2010). 
2.2.5 Cloning of the PCR products 
Cloning was done in the cloning room. To avoid resampling and PCR bias, 3 PCR products per 
isolate and time point that were previously genotyped were used for cloning. The PCR products 
were quantified to optimal concentration of 20 ng/µl before cloning using a Nanodrop 2000 
spectrophotometer (Thermo Scientific, South Africa). 
The PCR products were cloned into PCR2.1 TOPO vector, following the manufacturer‘s 
instructions (Invitrogen TOPO TA cloning kit, California). Briefly, in the ligation step the TOPO 
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cloning vector containing the deoxythymidine (T) overhangs was ligated to the PCR product 
which has deoxyadenosine (A) sticky ends. This is illustrated in the figure below: 
 
 
Figure 2.2: Illustration of the ligation step source: www.b2b.invitrogen.com  
The ligation reaction was prepared in 0.5ml RNase/DNase free microcentrifuge tubes as follows: 
Table 2.3: TOPO cloning reaction. 
Reagent Volume (µl) 
PCR product 2 
Salt solution 1 
Water 2 
TOPO cloning vector 1 
Final volume 6 
 
The reaction was incubated at room temperature for 30 minutes. For the transformation step, 2 µl 
of the ligation reaction was added to 1 vial of competent TOPO 10 E.coli cells. Care was taken 
not to mix by pippeting up and down as this would kill the cells. Transformations was carried out 
on ice for 30 minutes, heat shocked for 30 seconds in a water bath at 42ºC and cooled on ice for 
2 minutes. A volume of 250 µl of prewarmed SOC medium was added to the transformation and 
incubated in a Shaking incubator set at 230 rpm and at 37ºC for 1 hour. While waiting for the 1 
hour, 40 µl of X-gal was plated onto prewarmed LB/amp plates and incubated until use. For each 
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transformation, 100 µl and 50 µl was plated onto two separate LB/amp plates to ensure that one 
plate would have well-spread colonies. The plates were incubated at 37ºC for 16-18 hours. After 
incubation the positive transformants were indicated by white colonies.  
2.2.6 PCR screening of positive transformants. 
A master mix for the PCR screening was prepared using the reagents for the 2nd round of PCR 
amplification of HIV-1 pol region as described in Jennifer Giandhari thesis (2010). The primers 
used for the amplification is represented in the table below: 
Table 2.4: The HXB2 position and primers used to amplify the 1.7kb of HIV-1 pol.  
Primer name HXB2 position Primer sequences 5’-3’ 
AV150 (10pmol/µl) 2036-2062 F GTGGAAAGGAAGGACACCAAATGAAAG 
Pol M4 (10pmol/µl) 3892-3870 R CTATTAGCTGCCCCATCTACATA 
 
PCR master mix was prepared in a pre-amplification room. The PCR reagents were thawed and 
vortex for 5 seconds to mix and centrifuged briefly to collect content to the bottom of the tube.  
The PCR master mix was prepared in a 1.5 ml RNase/DNase free microcentrifuge tube as 
follows: 
Table 2.5: Reagents for the PCR master mix for screening colonies.  
Reagents Volume for 1 reaction (µl) Final Concentration 
10× buffer 2.5 1X 
dNTPs (10mM) 0.5 0.2mM 
AV150 (10pmol/µl) 0.5 0.2pmol/µl 
Pol M4 (10pmol/µl) 0.5 0.2pmol/µl 
Amplitaq Gold 5U/µl 0.125 0.025U/µl 
MgCl2 25mM 1.5 1.5mM 
DEPC treated water 9.375 - 
Final volume 15 - 
 
The PCR Master Mix was kept at -80ºC until added to the reaction tubes. The LB/amp plates that 
were used as master plates for the colonies were prewarmed in an incubator at 37ºC for 30 
minutes. The plates were labeled by drawing 40 grids lines and the grids were labeled 1 to 40. 
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After incubation, 40 white colonies were picked up using a 10 µl sterile pipette tip and touched 
on a master plate before proceeding with the PCR screening. The master plates were incubated at 
37ºC for 16-18 hours. Thirty colonies per sample were screened. A volume of 15 µl of distilled 
water was added to each reaction tubes. The colonies were transferred to each reaction tubes and 
heated in thermocycler for 5 minutes at 99.9ºC. The reaction tubes were centrifuged for 5 
minutes at 12000 ×g to separate the supernant from the pellet. A volume of 15 µl of the PCR 
master mix was added to each PCR reaction tubes. A volume of 10 µl of the supernant of the 
colonies was added to each reaction tube making it to final volume of 25 µl. Care was taken to 
open one tube at a time. The PCR screening was run on the thermocycler using the following 
conditions: 
Table 2.6 Cycling conditions for the 1st round PCR.  
Temperature Time Cycles 
94oC 2 minutes 1 
94oC 10 seconds  
50oC 30 seconds 10 
68oC 2 minutes  
94oC 15 seconds  
52oC 30 seconds 52 
68oC *2 minutes *plus 20 sec/cycle 
68oC 7 minutes 1 
4oC >10 minutes  
 
After the run, the PCR screening products were run on a 1% agarose gel to verify the presence 
positive insert with correct size band.  
A 1% agarose gel was prepared by adding 0.5 g of agarose tablet to 50 ml of 1×TBE buffer. The 
agarose was allowed to dissolve and heated in a microwave until all the agarose was completely 
dissolved and the solution was clear. The solution was cooled and poured into prepared casting 
trays with combs and the gel was left to set for 30 minutes at room temperature. After 30 
minutes, the combs were removed and the gel was placed in the electrophoresis tank. The 
1×TBE buffer was poured into the electrophoresis tank up to the level that covered the gel. The 
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gel loading dye was prepared in a 1.5ml tube by adding 1 µl of the gel red to 50 µl of gel 
loading. Five µl of the PCR product was mixed with 1µl of the gel loading dye and loaded into 
the wells. Two µl of 1kb DNA ladder was also mixed with 1 µl of gel loading dye and loaded to 
the first well of the gel. The gel was run for 45 minutes at 100V on Enduro electrophoresis 
power supply (Denville Scientific Inc). After the run, the gels were viewed with GelVue UV 
transilluminator (GENEsnap) and the images were captured. The correct size of the PCR product 
was estimated by comparing it to the size of the different products of the 1kb DNA ladder as 
illustrated below:  
                                              
Figure 2:3. An Agarose gel electrophoresis of the PCR screen with the correct size of the insert 1.7 kb 
(right). O‘ Generuler 1kb DNA ladder (left) showing the size of the different products of the gel/ladder 
(Invitrogen).   
2.2.7 Growing of positive clones and Plasmid DNA (pDNA) extractions  
Thirty positive colonies per isolate were grown. This has been statistically proven in other 
studies that in order to detect minority variants at 10% of the viral population, at least 30 clones 
have to be analysed. 
LB broth was prewarmed in incubator at 37ºC for 30 minutes. A volume of 5ml of LB broth and 
5 µl of ampicillin was added to 15ml centrifuge tube. The positive clones were picked from the 
master plates using quadloop and added to the centrifuge tube with LB and ampicillin. The tubes 
were place in a rack positioned horizontally in shaking incubator at 37ºC and 230 rpm for 16-18 
Positive insert with 
correct size band (1.7 kb) 
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hours. After incubation, the glycerol stocks for each clone were prepared as follows: The 
glycerol was heated in a microwave until it was warm. A volume of 150 µl of glycerol was 
added to 1.5 ml cryovial tubes. A volume of 850 µl of cell suspension was added to the cryovial 
tubes with glycerol making the total volume to 1000 µl. Care was taken to open one tube at a 
time. The glycerol stocks were stored at -80ºC for long term use. The remaining cell suspension 
was centrifuge at 12000 ×g for 2 minutes as follows:  
A volume of 1000 µl of cell suspension was added to 1.5 ml tube using a Plastic Pasteur pipette 
and centrifuge for 2 minutes at 12000 × g. The supernatant was discarded and the pellet was 
kept. Additional volume of 1000 µl was added to the same tube with the pellet and process was 
repeated until all the cell suspension was finished. The pellet (pDNA) was purified using 
GeneJet plasmid miniprep kit following manufactures instructions (fermantas miniprep kit). 
Distilled water was used to elute the pDNA instead of the provided elution buffer. The Plasmid 
DNA was stored at -20oC until used.  
To confirm the present of both the vector and the insert, a restriction digest was performed. The 
pDNAs were quantified using a Nanodrop. The restriction digest mix was prepared as follows: 
Table 2.7: Reagents for the restriction digest.  
Reagent Volume for 1 reaction (1µl) Final concentration 
10× Ecori Buffer 1 1X 
Ecori Enzyme 2000U/µl 0.5 20U/µl 
Distilled water 7.5 - 
Final volume 9 - 
A volume of 9 µl of the mix was added to each reaction tubes. One µl of the pDNA was added to 
each reaction tube making it to final volume of 10 µl. The reaction was run on the thermocycler 
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Table 2.8 Cycling conditions for the restriction digest.  




After the run, the restriction digest was analyzed by running in a 1% gel electrophoresis as 
described in 2.2.5. This is illustrated in the figure below: 
 
 
Figure 2.4: An Agarose gel electrophoresis of the restriction digest.  
2.2.8 Sequencing of Plasmid DNA (pDNA) 
The pDNAs were diluted to 50 ng/µl which is an optimal concentration for sequencing of the 
pDNA. The HXB2 position and sequences of the 4 primers used for the sequencing of HIV-1 pol 
are represented in the table below:  
Table 2.9: The HXB2 position and primers used to sequence the 1.7 kb of HIV-1 pol.  
Primer name HXB2 Position Primer sequence (5’-3’) 
AV150 (3.2 pmol/µl) 2036→2062 F GTGGAAAGGAAGGACACCAAATGAAAG 
Pol M4 (3.2 pmol/µl) 3892←3870 R CTATTAGCTGCCCCATCTACATA 
Pol MG (3.2 pmol/µl) 2823←2798 R ATTGAACTTCCCAGAAGTCTTGAGTT 
Pol M1 (3.2 pmol/µl) 2251→2272 F GTTAAACAATGGCCATTGACAGA 
 
Plasmid (3.9 kb)  
Insert (1.7 kb) 
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The figure below illustrates the outline of the 4 primers, showing how the forward and the 
reverse primers overlap. 
 
Figure 2.5: Diagram illustrating the layout of primers used for sequencing of HIV-1 Pol gene.  
The reagents for the sequencing reaction were thawed, vortex (except for the Ready reaction mix) and 
centrifuge briefly. A master mix for each primer was prepared as follows: 
Table 2.10: Reagents for the sequencing reaction.  
Reagents Volume (µl) Final concentration 
Big Dye ready reaction mix 0.4 - 
5×sequencing buffer 2 1× 
Primer (3.2 pmol/µl) 1 0.32 pmol/µl 
Water 3.6 - 
Final Volume 7 - 
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The sequencing reaction was set up in a MicroAmp optical 96-well reaction plate. A volume of 7 
µl of each reaction primer mix was added to the selected wells and 3 µl of diluted PCR product 
(50 ng/µl) was also added and mixed with pipette tips. The plates were sealed with a covering 
mat and vortexed briefly. The sequencing reaction was run in the thermocycler under the 
following conditions: 
Table 2.11 Cycling conditions for the sequencing reaction.  
Temperature Time Cycles 
96 0C 1 min 1 
96 0C 10 sec  
50 0C 5 sec 35 
60 0C 4 min  
4 0C Hold - 
 
After the run, the sequencing products were purified on the same day. Firstly, a mixture of 3M 
Sodium acetate (NaOAc) pH 5.2 and 100% Ethanol was prepared as follows: 
Reagent 1 well (µl) 
3M NaOAc pH 5.2 1 
100% Ethanol 25 
Final Volume 26 
 
A volume of 1 µl of 125 mM EDTA pH8.0 was added to each well and mixed with pipette tips. 
A Volume of 26 µl of the mixture prepared above was added to each well using multi- channel 
pipette tips. The plate was covered with an adhesive foil and was vortex briefly before 
centrifuged at 3000 × g for 20 minutes using an Eppendorf plate centrifuge. The plate was 
carefully inverted onto paper towel and centrifuged at 150 × g for 5 minutes. A 70% cold ethanol 
was prepared and 35 µl of the solution was immediately added to the each well and the plate was 
covered once again with an adhesive foil and centrifuge at 3000 × g for 5 minutes. The plate was 
inverted once more onto paper towel and centrifuge for 1 minute at 150 × g and dry in the 
thermocycler at 50oC for 5 minutes in dark place. The plate was sealed with an adhesive foil and 
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covered with a foil and stored at -20oC until sequenced. Before sequencing, 10 µl of Formamide 
was added to the dried pellet in each well and heated in a thermocycler for 3 minutes at 95oC.  
The plates were loaded onto the ABI 3130 Genetic analyzer (Applied Biosystems, California). 
2.2.9 DNA Sequence analysis 
Sequence analysis was done on a Linux computer using the Phred and Phraph and consed 
sequence editing programme. The sequences were aligned using CLUSTALW and manually 
edited by codon alignment using the Genetic Data Environment (GDE) program or BioEdit. 
Final consensus sequences were submitted to Stanford drug resistance database & REGADB 
sequence analysis tools which gave a list of protease and reverse transcriptase mutations 
associated with RT and PR inhibitors (Chapter 1.8.1 and 1.8.2).  
2.2.9.1 Phylogenetic analysis  
Preliminary phylogenetic trees were performed for quality control of the sequences i.e. to 
exclude contamination between samples. Trees were generated using PAUP* 4b.10 by means of 
the neighbor joining method (Chapter 1.9.1.1). A F84 model of substitution was used. Trees 
were viewed using figtree v1.4.  
Maximum likelihood trees for each patients were constructed in PAUP*4.0b10 using the 
appropriated evolutionary model selected by the AIC in MODELTEST 3.7. With this method, a 
neighbor joining tree was calculated using JC69 model of evolution. The likelihood ratios test 
statistic was also calculated and the programme selected the appropriate model based on the P- 
Values of the likelihood ratio test. Trees were rooted using the ―best fit root‖ as estimated using 
the Path-O-Gen v.1.4. Trees were viewed using Figtree v.1.4.  
2.2.9.2 Genetic diversity 
The genetic diversity (evolutionary distance) within and between the sequences from the two 
time points was determined using the Maximum Composite Likelihood (MCL) method 
implemented in MEGA software version 4.0 (Tamura et al., 2007).  
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2.2.9.3 Analysis of selective pressure. 
Positive selection was assessed using HyPhy software package in Datamonkey (chapter 1.7.4). 
The IFEL model was used to estimate the ratio of nonsynonymous (dN) to synonymous (dS) 
amino acid substitution as a determinations of natural selection. Positive selection was 
characterized as dN/dS ratio greater than 1. The HKY85 model of substitution was used with 
0.05 significant levels.  
2.2.9.4 Identification of the signature amino acid difference between the sequences at two 
time points using VESPA 
The Viral Epidemiology Signature Pattern Analysis (VESPA) analysis tool is used to detect 
signature amino acid difference between two groups i.e. the query sequences and the background 
sequences VESPA determine the frequency of amino acids at each position in the aligned 
sequence in each group. The VESPA report shows the signature sequence that indicates the 
common positions in the query sequence that differ from the reference sequence. It also shows 
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2.3 Results  
2.3. Minority variants of the HIV-1 Pol region. 
2.3.1.1 Longitudinal analysis of patients that were switched from 1st to 2nd line therapy   
None of these patients developed PI resistance mutations when switched on to PI inclusive 
regimen. Additional RT mutations that were not detected by the standard genotyping were 
detected before and after switching to PI inclusive regimen. Specifically, this included NNRTI 
mutations from the 1st line failure and NRTI from 2nd line failure (PCSM012) and the NNRTI 
mutations from 2nd line failure (PCSM004 and PCSM009).  
2.3.1.1.1 Longitudinal analysis of PCSM004   
For PCSM004, a total of 58 HIV-1 Pol gene sequence were analyzed: 30 sequences at the 1st and 
28 sequences at the 2nd time point. At the 1st time point, the RT drug resistance mutations 
detected by standard genotyping included the major NRTI mutations (M41L, M184V) and 
NNRTI mutations (V106M, V179D, K103R and F227L). No additional mutations were detected 
by cloning. The frequency of most of these mutations were also high (>97%) at this time point. 
After nine months, a 2nd genotype was performed. No mutations were detected by standard 
genotyping at the 2nd time point (Figure 2.6). However, the NNRTI mutations (V106M and 
V179D) were detected by cloning (Figure 2.6). The frequency of these mutations decreased from 
97% to 4% (V106M) and from 97% to 14% (V179D) at the 2nd time point (Table 2.12). No 














Figure 2.6: Graphical summary of drug resistance history and the resistance profile of PCSM004. 
The CD4 cell count (blue) is represented on the left y-axis and the viral load (red) is on the right y-axis. 
The PIs are represented by the purple bars, NRTIs by the blue bars and NNRTIs by the brown bars. The 
x-axis represents time. The boxes show the mutations detected by standard genotyping and cloning during 
the two time points. Red mutations are additional mutations detected only by cloning. 
Table 2.12: The frequency of mutations at the 1st and 2nd time points for PCSM004. 
Mutations  Frequency of mutation (%) 
PI 1st time point 2nd time point 
- - - 
NRTI   
M41L 73 0 
M184V 97 0 
NNRTI   
V106M 97 4 
V179D 97 14 
K103R 93 0 
F227L 33 0 
 
1st time point  
PR: None  
NRTI: M41L, M184V 
NNRTI: V106M, V179D, K103N, 
F227L 
2nd time point 
PR: None 
NRTI: None 
NNRTI: V106M, V179D 
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2.3.1.1.2 Longitudinal analysis of PCSM009 
For PCSM009, a total of 53 HIV-1 Pol gene sequence were analyzed: 23 sequences at the 1st and 
30 sequences at the 2nd time point. At the 1st time point, the RT drug resistance mutations 
detected by standard genotyping included the major NRTI mutations (D67N and M184V) and 
NNRTI mutations (K101E, V106M, E138G/K and G190A). No additional mutations were 
detected by cloning. The frequency of most of these mutations were also high (> 65%) except for 
E138G which had a frequency of 9% (Table 2.13) at this time point. After twelve months, a 2nd 
genotype was performed. No mutations were detected by standard genotyping at the 2nd time 
point (Figure 2.7). The mutations only detected by cloning included the NRTI mutation D67G 
and NNRTI mutations (K101E, V106M, E138G and G190A) from the 1st time point (Figure 2.7). 
However, the frequency of these mutations was low (<10%) (Table 2.13). No mutations were 






Figure 2.7: Graphical summary of drug resistance history and the resistance profile of 
PCSM009.  
 
1st time point  
PR: None  
NRTI: D67N/G, M184V 
NNRTI: K101E, V106M, 
E138G/K/, G190A 
 
2nd time point 
PR: None   
NRTI: D67G 
NNRTI: K101E, V106M, 
E138G, G190A 
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Table 2.13: The frequency of mutations at the 1st and 2nd time points for PCSM009 
Mutations  Frequency of mutations (%) 
PI 1st time point 2nd time point 
- - - 
NRTI   
D67G 0 3 
D67N 65 0 
M184V 100 0 
NNRTI   
K101E 100 10 
V106M 100 10 
E138G 9 7 
E138K 91 0 
G190A 100 10 
 
2.3.1.1.3 Longitudinal analysis of PCSM012   
For PCSM012, a total of 62 sequences were analyzed: 35 sequences at the 1st and 29 sequences 
at the 2nd time point.  At the 1st time point, the RT drug resistance mutations detected by standard 
genotyping included the major NNRTI mutation K103N (figure 2.8). Additional mutations 
detected by cloning included the NRTI mutation T69A and NNRTI mutations: V106M, E138K 
and G190A. The frequencies of most of these additional mutations were low (≥ 3%) (Table 
2.14). After eight months, a 2nd genotype was performed. The NRTI mutation T69A and NNRTI 
mutation K103N were still detected, with an increase in frequency from 14%- 62%  (T69A) and 
26%  to 66% for K103N (Table 2.14). The NRTI mutation T69D was detected by standard 
genotyping at this time point, however the frequency of this mutation in the clones was low (3%) 
(Table 2.14). The V106M, E138K and G190A mutations were not detected at this time point. No 
mutations were detected in PR at either time points for both standard genotyping as well as 
cloning.   . 






Figure 2.8: Graphical summary of drug resistance history and the resistance profile of 
PCSM012. 
Table 2.14: The frequency of mutations at the 1st and 2nd time points for PCSM012. 
Mutations  Frequency of mutations (%) 
PI 1st time point 2nd time pint 







T69D 0 3 
NNRTI    
K103N 26 66 
V106M 9 0 
E138K 3 0 
G190A 3 0 
 
1st time point  
PR: None 
NRTI: T69A 




2nd time point  
PR: None  
NRTI: T69A, T69D  
NNRTI: K103N 
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2.3.1.2 Longitudinal analysis of patients that remained on 2nd line therapy. 
All these patients had several PR and RT while on PI inclusive regimen, with the exception of 
PCSM002 which only harbored M148V. Additional mutations were detected by cloning in the 
PR as well as in the RT region. 
2.3.1.2.1 Longitudinal analysis of PCSM001   
For PCSM001, a total of 57 HIV-1 Pol sequences were analyzed: 29 sequences were analyzed at 
the 1st and 28 sequences at the 2nd time point. At the 1st time point, the PR drug resistance 
mutations detected by standard genotyping included the mutations M46I, I54V, L76V, I84V and 
the minor (secondary) mutations L10F and K20R. The frequency of most of these mutations was 
> 55% (Table 2.15). Additional mutations detected by cloning included the major mutations 
I47V and I54L. The frequency of mutation I47V was low (3%) while for I54L it was high (66%) 
(Table 2.15). The RT drug resistance mutations included the NRTI mutations T69N, L74V, 
M184I/V, T215F, and K219Q and NNRTI mutations L100I, K103N, H221Y and M230L. The 
frequency of these mutations was high (≥ 93%). Additional mutations detected by cloning 
included the NRTI mutation D67N and the NNRTI mutation V106M. The frequency of this 
mutation was also high (67%). After one month, a 2nd genotype was performed. The majority of 
the PR and RT mutations that were detected at the 1st time point were still present except for PR 
mutations I54V and I47V (Figure 2.9 and table 2.15). The frequency of most of these remained 
the same (<100%). However, the frequency of PR mutations L10F and the additional mutation 
I54L which was detected by cloning increased to 97% while the frequency of RT Mutations 
M184I and K103N decreased to 3% and 21% respectively (Table 2.15)    
 



















1st time point 
PR: L10F, M46I, I47V, K20R, 
I54V, I54L, L76V, V82A, I84V, 
NRTI: D67N, T69N, L74V, 
M184I/V, T215F, K21Q 
NNRTI: L100I, K103N, V106M, 
H22IY, M230L 
 
2nd time point  
PR: L10F, M46I, K20R, I54V, 
I54L, L76V, I84V, 
NRTI: T69N, L74V, M184I/V, 
T215F, K219Q 
NNRTI: L100I, K103N, H22IY, 
M230L 
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Table 2.15: The frequency of mutations at the 1st and 2nd time point for PCSM001.  
Mutations  Frequency of mutations (%) 
PI  1st  time point 2nd time point 
L10F 67 97 
K20R 100 93 
M46I 100 100 

















            67 
 
              0 
T69N 93 97 
L74V 93 93 
M184I 62 3 
M184V 100 90 
T215F 93 93 
K219Q 93 97 
NNRTI   
L100I 93 93 
K103N 86 21 
V106M 67 0 
H221Y 93 97 
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2.3.1.2.2 Longitudinal analysis of PCSM002  
For PCSM002, a total of 55 sequences HIV-1 Pol were successfully analyzed: 28 sequences at 
the 1st and 27 sequences at the 2nd time point. At the 1st time point, the PR drug resistance 
mutations detected by standard genotyping included the major PI mutations M46I, I54V, T74S, 
V82A and the minor mutation K20R. The frequency of most of these mutations was high 
(>71%) (Table 2.16). Additional mutations detected by cloning included the minor mutation 
L10F and the frequency of this mutation was low (4%). The RT resistance mutations detected by 
standard genotyping included the NRTI mutation M184V. The frequency of this mutation was 
also high (89%) (Table 2.16). No NNRTI mutations were detected by standard genotyping and 
cloning.  After two months, a 2nd genotype was performed. The PR resistance mutations detected 
at 1st time point was still detected (Figure 2.10 and Table 2.16). The frequency of these 
mutations remained the same while the frequency of L10F increased from 4% to 93% at this time 






Figure 2.10: Graphical summary of drug resistance history and the resistance profile of PCSM002. 
1st time point  
PR:  M46I, I54V, T74S, 




2nd time point  
PR: M46I, I54V, T74S, 
V82A, L10F, K20R,  
NRTI: M184V 
NNRTI: None  
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Table 2.16: The frequency of mutations at the 1st and 2nd time point for PCSM002.  
Mutations Frequency of mutations (%) 
PR 1st time point 2nd time point 
L10F 4 93 
K20R 100 93 
M46I 100 93 
I54V 71 93 
T74S 100 93 
V82A 89 93 
NRTI   
M184V 89 93 
NNRTI - - 
  
2.3.1.2.3 Longitudinal analysis of PCSM007   
For PCSM007, a total of 58 HIV-1 Pol sequences were analyzed: 30 sequences at the 1st and 28 
sequences at the 2nd time point were successfully analyzed. At the 1st  time point, the PR drug 
resistance mutations detected by standard genotyping included the major PI mutations M46I, 
I54V, A71V, L76V, V82A and the minor mutation L10F (Figure 2.11; Table 2.17). The 
frequency of these mutations was >50% at this time point (Table 2.17). Additional mutation 
detected by cloning included the major mutation K20R. The frequency of this mutation was 50% 
(Table 2.17). The RT drug resistance mutations detected by standard genotyping included the 
NRTI mutations D67N, M184V and NNRTI mutations, K103N, V106M. The frequency of the 
D69N, K103N and V106M mutations was high (>93%) while M184V was low (43%). 
Additional mutations detected by cloning included the NRTI mutation K70R and NNRTI 
mutations K101E, E138K and G190A. The frequency of K70R was 53%, while the frequency of 
K101E, E138K and G190A was the same (14 %) as they occurred in the same clones. After two 
months, a 2nd genotype was performed. The PR resistance mutations detected at the 1st time point 
was still detected. However, there was an increase in the frequency of these mutations e.g. L10F 
(82%), A71V (79%) and L76V (89%). An additional mutation K20R was still detected as well. 
  60 
 
However, the frequency of this mutation was low (18%) (Table 2.17) and the RT resistance 
mutations were still detected. The frequency of the RT mutations D69N, K103N and V106M did 
not change dramatically, while the frequency of mutations K70R, E138K and G190A increased 
to 57% (Table 2.17). Additional mutation detected by cloning at this time point was M184V. 













1st time point  
PR: L10F, M46I, 154V, V82A,  
NRTI: D67N, M184V, K70R, 
NNRTI: K103N, V106M, E138K, 
G190A 
 
2nd time point  
PR: L10F, K20R, M46I, 154V, V82A, 
A7IV, L76V 
NRTI: D67N, M184V, K70R 
NNRTI, K101E K103N, V106M, 
E138K, G190A 
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Table 2.17: The frequency of mutations at the 1st time point and 2nd time point for 
PCSM007 
Mutations Frequency of mutations 
(%) 
PR 1st time point 2nd time 
point 
L10F 57 82 
K20R 50 18 
M46I 87 96 
I54V 87 18 
A71V 50 79 
L76V 50 89 
V82A 87 96 
NRTI   
D69N 96 96 
K70R 53 14 
M184V 43 14 
NNRTI   
K101E 0 57 
K103N 93 96 
V106M 100 96 
E138K 14 57 
G190A 14 57 
 
2.4 Phylogenetic analysis  
Phylogenetic analysis was performed to assess the evolution of the virus as well as to assess the 
relationship between the sequences with PI resistance mutations at the 1st and the 2nd time point. 
Maximum likelihood (ML) trees for each patients were constructed in PAUP*4.0b10 using the 
appropriated evolutionary model selected by the AIC in MODELTEST 3.7. In the patients that 
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remained on 2nd line therapy in both time points, the HKY+ I+G model was selected in two 
patients (PCSM001 and PCSM007) while GTR +I +G model was selected for PCSM002. In 
patients that were switched from 1st to 2nd line therapy, TVM +I+G model was selected for 
PCSM009 and PCSM012 while K81uf +I+G was selected for PCSM004. The trees were rooted 
with the ‗best fit root‘ as determined by Path-O-Gen V.1.4. Trees were viewed with Figtree 
v1.1.4.  
2.4.1 Phylogenetic analysis of the patients that remained on 2nd line therapy. 
There was intermingling between the sequences at the 1st and the 2nd time point, with the 
exception of PCSM007 where there was no intermingling of the sequences between the time 
points. Collectively, the tree topologies of these patients were not only due to the effect of drug 
of drug resistance mutations as the analysis of the trees where the drug resistance mutations were 
removed showed similar analysis (data not shown).  
2.4.1.1 Phylogenetic analysis and intra sequence diversity of PCSM001  
For PCSM001, the phylogenetic tree had eight clusters: four showing the intermingling between 
the sequences at the 1st (red circles) and the 2nd  time point (green circles) (Clusters 1-3 and 8) 
and three clusters only with sequences from the 2nd  time point (cluster 4-6) and one cluster only 
with sequences from the 1st time point (cluster 7) (Figure 2.12). Clusters 1, 2 and 8 had a diverse 
pattern characterized by both long and short branch lengths, suggesting that there is distinctive 
evolutionary pressure acting on the different virus thus leading to this diverse branch lengths 
pattern (Fischer et al., 2012). This could be amino acid sites selected under drug selective 
pressure. Clusters 3 and 7 showed long branches of similar lengths, while clusters 4-6 had short 
branch lengths suggesting less diversity in these sequences.  
The intra -sequence diversity at each time point and between the time points is represented in the 
table alongside the phylogenetic tree (Figure 2.12). The intra sequence diversity at the 1st time 
point was 0.8% (SE ±0.1%)  (Figure 2.12) and decreased slightly at the 2nd time point to 0.6% 
(SE ± 0.1%) while the diversity between the time points was 0.7% (SE ± 0.01%). 
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2.4.1.1.1 Phylogenetic analysis of PCSM001 investigating the evolution of PI resistance 
mutations at the 1st and the 2nd time point.  
In this patient the sequences harboring the same resistance mutations clustered together. These 
clusters included both the 1st and 2nd time point sequences, suggesting that the viral population at 
the 2nd time point evolved from the mutant population detected at the 1st  time point (Halvas et 
al., 2010). Specifically, the 1st  time point sequences harboring the genotypes: L10F, K20R, 
M46I, L76V, V82A, V84I (blue squares); K20R, M46I, I54V, L76V, V82A, V84I (green 
squares); K20R, M46I, I54V, L76V, V82A (brown squares), L10F,  K20R, M46I, I47V, L76V 
(black squares) and L10F, K20R, M46I, L76V(orange squares) intermingled with the mutant 
sequences at the 2nd  time point harboring the genotype L10F, K20R, M46I, L76V (orange 
square) (Figure 2.12). Interestingly, there was only one genotype observed at the 2nd time point 
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Figure 2.12: Maximum likelihood (ML) trees of the HIV-1 pol region of PCSM001.The ML was 
constructed using the HKY+ I+ G model of evolution selected by AIC implemented in the MODELTEST 
3.7. The scale bar at the bottom of the tree indicates the number of nucleotide substitutions per site. Red 
circles represent the sequences at the 1st time point while the green circles represent the sequences at the 
2nd time point. The squares represent the genotypes for the PR region. The intra sequence diversity and 
the standard error (SE) at the 1st and the 2nd time point and between the time points are represented in the 
table alongside the tree. The numbers the right-hand-side of tree represent the phylogenetic clusters. 
Additionally, the same ML tree was also analyzed to investigate the evolution of NNRTI and 
NNRTI mutation overtime. Again, the sequences harboring the same RT resistance mutations 
clustered together (Figure 2.13). This clusters included the 1st and the 2nd time point sequences. 
In cluster 1, the 1st time point sequences harboring the genotypes: D67N, T69N, L74V, L100I, 
K103N/S,V106M, M184V/I, T215F, K219Q, H221Y, M230L (blue squares) and T69N, L74V, 
L100I, K103N, M184V, T215F, K219Q, H221Y, M230L (green squares) intermingled with the 
sequences at the 2nd time point harboring the genotypes: T69N, L74V, L100I, K103S, M184V, 
T215F, K219Q, H221Y, M230L and one sequence with genotype T69N, L74V, L100I, K103N, 
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M184I, K219Q, H221Y, M230L (pink squares). In clusters 2, the 1st  time point sequences 
harboring the genotype T69N, L74V, L100I, K103N, M184V, T215F, K219Q, H221Y, M230L 
(green squares) intermingled with the 2nd time point sequences harboring the genotype T69N, 
L74V, L100I, K103S, M184V, T215F, K219Q, H221Y, M230L (purple squares) and one 
sequence with no mutations (orange squares). Cluster 3 also showed intermingling of the 1st time 
point sequences with the genotype: T69N, L74V, L100I, K103S, M184V, T215F, K219Q, 
H221Y, M230L (purple squares); D67N, T69N, L74V, L100I, K103N/S, V106M, M184V/I, 
T215F, K219Q, H221Y, and M230L (blue squares). Again cluster 8 showed intermingling of the 
1st and 2nd time point sequences where the 1st time point harbored the genotype D67N, T69N, 
L74V, L100I, K103N/S,V106M, M184V/I, T215F, K219Q, H221Y, M230L (blue squares); 
T69N,  L74V, L100I, K103N, M184V, T215F, K219Q, H221Y, M230L (green squares) and one 
sequences with genotype D67N,  K103N, V106M, M184V (brown squares). Clusters 4-6 had  
sequences from the 2nd  time point only harboring  the genotypes: T69N, L74V, L100I, K103S, 
M184V, T215F, K219Q, H221Y, M230L (purple squares); T69N,  L74V, L100I, K103N, 
M184V, T215F, K219Q, H221Y, M230L (green squares) and T69N, L74V, L100I, K103N, 
M184V, T215F, K219Q, H221Y, M230L (red  squares), while cluster 7 had only sequences from 
the 1st time point only with the genotype D67N, T69N, L74V, L100I, K103N/S,V106M, 
M184V/I, T215F, K219Q, H221Y, M230L (blue squares).  
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Figure 2.13: Maximum likelihood (ML) trees of the HIV-1 pol region of PCSM001 showing the 
evolution of RT resistance overtime. Red circles represent the sequences at the 1st time point while the 
green circles represent the sequences at the 2nd time point. The squares represent the genotypes at for the 
RT region. 
2.4.1.2 Phylogenetic analysis and intra sequence diversity of PCSM002 
In PCSM002, the phylogenetic tree had seven clusters: five showing the intermingling between 
the sequences at the 1st and the 2nd time point (Clusters 2, 4-7) and two clusters only with 
sequences from the 1st time point (clusters 1 and 3). Clusters 2, 4-6 and 7 showed both long and 
short branch lengths. Cluster 1 showed branches of similar lengths, while cluster 3 had short 
branch lengths compared to the other branches, suggesting less diversity in these sequences. The 
intra -sequence diversity at each time point and between the time points is represented in the 
table alongside the phylogenetic tree (Figure 2.14). The intra sequence diversity at the 1st time 
point was 0.8% (SE ± 0.1%) (Figure 2.14) but decreased slightly at the 2nd time point to 0.6% 
(SE ± 0.1%) while the diversity between the time points was 0.8% (SE ± 0.1%). 
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2.4.1.2.1 Phylogenetic analysis of PCSM002 investigating the evolution of PI resistance 
mutations at the 1st and the 2nd time point.  
Again, the sequences harboring the same resistance mutations clustered together. These clusters 
included both 1st time point and 2nd time point sequences. The 1st time point sequences harboring 
the genotypes: L10F, K20R, M46I, I54V, T74S, V82A (blue squares); K20R, M46I, I54V, T74S 
(orange squares); L10F, K20R, M46I, T74S, V82A (green squares) and K20R, M46I, T74S, 
V82A (pink squares) intermingled with the sequences at the 2nd time point. All but two 
sequences at the 2nd time point harbored the K20R, M46I, I54V, T74S, V82A genotype (brown 
squares). The remaining two sequences only showed the L10F mutation in the PR (purple 
squares) (Figure 2.14 A).   
 
Figure 2.14: Maximum likelihood (ML) trees of the HIV-1 pol region of PCSM002.The ML was 
constructed using the GTR + I+ G model of evolution selected by AIC implemented in the MODELTEST 
3.7. The scale bar at the bottom of the tree indicates the nucleotide substitution per site. Red circles 
represent the sequences at the 1st time point while the green circles represent the sequences at the 2nd time 
point. The squares represent the genotypes at the PR. The intra sequence diversity and the standard error 
(SE) at the 1st and the 2nd time point and between the time points are represented in the table alongside the 
tree. The numbers alongside the tree represent the phylogenetic clusters. 
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Figure 2.14 A. ML tree indicating the sub tree showing the two sequences with the L10F mutation 
in PR (Purple).   
Again, the same ML tree was also analyzed to investigate the evolution of NNRTI and NNRTI 
mutation overtime. In this patient, the majority of the sequences in both time points had the 
mutation M184V with a few sequences which were wild type (Figure 2.15). This suggests 
M184V was the fit mutation and might have increased treatment failure. Additionally, there was 
no evolution of RT resistance overtime suggesting that the M184V at the 1st time point   
persisted to 2nd time point.  
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Figure 2.15: Maximum likelihood (ML) trees of the HIV-1 pol region of PCSM001 showing the 
evolution of RT resistance overtime. Red circles represent the sequences at the 1st time point while the 
green circles represent the sequences at the 2nd time point. The squares represent the genotypes at for the 
RT region. 
2.4.1.2 Phylogenetic analysis and intra sequence diversity of PCSM007 
For PCSM007, the phylogenetic tree had five clusters: two showing the sequences from the 1st 
time point only (clusters 1 and 2) and three clusters showing the sequences from the 2nd  time 
point (Clusters 3-5) (Figure 2.16). Only three sequences from the 1st time point clustered with the 
sequences from the 2nd time point suggesting that the sequences at the 2nd time point evolved 
from the sequences detected at the 1st time point. Clusters 1 and 2 had longer branch lengths 
indicating high diversity in those sequences. Cluster 3-5 showed short branch lengths of similar 
lengths, specifically in clusters 4 and 5, with only a few sequences with longer branch lengths 
(clusters 3 and 5). 
The intra sequence diversity at the 1st time point was high: 1.3 % (SE ± 0.2%) but decreased at 
the 2nd time point to 0.6 % (SE ± 0.1), while the diversity between the time points was 1.4% (SE 
±0.2%).  
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2.4.1.2.1 Phylogenetic analysis of PCSM007 investigating the evolution of PI resistance 
mutations at the 1st and the 2nd time point. 
Again, the sequences harboring the same resistance mutations clustered together (Figure 2.16).  
The 1st time point sequences harbored the genotypes: L10F, K20R, M46I, I54V, A71V, L76V, 
V82A (green squares), L10F, M46I, I54V, L71V, L76V, V82A (black squares), K20R, M46I, 
I54V, A71V, L76V, V82A (blue squares), K20R, M46I, I54V, L76V, V82A (brown squares), 
and one sequences which had no mutations (orange squares). The majority of the sequences at 
the 2nd time point harbored the genotype: L10F, M46I, I54V, V82A (purple squares). The 
remaining sequences harbored the genotypes: L10F, K20R, M46I, I54V, A71V, L76V, V82A 
(green squares), K20R, M46I, I54V, A71V, L76V, V82A (blue squares), M46I, I54V, V82A 
(pink squares) and few which were wild types (orange squares). Interestingly, only two 
genotypes detected at the 1st time point were observed at the 2nd time point i.e. genotypes: L10F, 
K20R, M46I, I54V, A71V, L76V, V82A (green squares) and K20R, M46I, I54V, A71V, L76V, 
V82A (blue squares) (Figure 2.16). 
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Figure 2.16: Maximum likelihood (ML) trees of the HIV-1 pol region of PCSM007. The ML was 
constructed using the HKY+ I+G model of evolution selected by AIC implemented in the MODELTEST 
3.7. The scale bar at the bottom of the tree indicates the nucleotide substitution per site. Red circles 
represent the sequences at the 1st time point while the green circles represent the sequences at the 2nd time 
point. The squares represent the genotypes at the PR. The intra sequence diversity and the standard error 
(SE) at the 1st and the 2nd time point and between the time points are represented in the table alongside the 
tree. The numbers alongside the tree represent the phylogenetic clusters. 
Again, the same ML tree was also analyzed to investigate the evolution of NNRTI and NNRTI 
mutation overtime. Again, the sequences harboring the same RT resistance mutations clustered 
together (Figure 2.17). The majority of the sequences at the 1st time point harbored the genotype 
D67N, K103N, V106M (pink squares) with a few sequences harboring the genotype D67N, 
K70R, K103N, V106M, E138K, M184V, G190A (purple squares) and one sequences which was 
wild type (orange squares). This patient harbored more diverse genotypes at the 2nd time point: 
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D67N, K70R, K101E, K103N, V106M, E138K, G190A (blue squares), D67N, K103N, V106M, 
M184V (green squares), D67N, K103N, V106M (pink squares) and one sequence harboring the 
genotype K70R, K101E, V106M, E138K, M184V, G190A (brown squares). 
 
Figure 2.17: Maximum likelihood (ML) trees of the HIV-1 pol region of PCSM007 showing the 
evolution of RT resistance overtime. Red circles represent the sequences at the 1st time point while the 
green circles represent the sequences at the 2nd time point. The squares represent the genotypes at for the 
RT region. 
2.4.2 Phylogenetic analysis of the patients that were switched from 1st to 2nd line therapy. 
There was no intermingling between the sequences at the 1st and the 2nd time point, with the 
exception of PCSM012 where a few sequencing from 1st time point intermingled with the 
sequences at the 2nd time point. Again, the tree topologies of these patients were not only due to 
the effect of drug resistance mutations as the analysis of the trees where the drug resistance 
mutations were removed showed similar analysis (data not shown). 
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2.4.2.1 Phylogenetic analysis and intra sequence diversity of PCSM004 
PCSM004 showed two distinct populations of sequences, one with the sequences at the 1st time 
point and the other with the sequences at the 2nd time point (Figure 2.18). The phylogenetic tree 
had seven clusters: three showing the sequences from the 1st time point (clusters 1-3) and four 
clusters showing the sequences from the 2nd time point (clusters 4-7). There was no 
distinguishing pattern between these clusters as they are characterized by both long and short 
branch lengths, again suggesting that there is distinctive evolutionary pressure acting on the 
different virus thus leading to this diverse branch lengths pattern (Fischer et al., 2012).  
The intra sequence diversity at the 1st and the 2nd time point was low i.e. 0.7% (SE= 0.1%) while 
the diversity between the time point was high 1.8 % (SE = 0.3%) (Figure 2.18). 
 2.4.2.1.1 Phylogenetic analysis of PCSM004 investigating the evolution of RT resistance 
mutations at the 1st and the 2nd time point. 
In this patient the sequences harboring the same resistance mutations clustered together. 
However, there was no intermingling between sequences from the 1st time point (clusters 1-3) 
and the 2nd time point (clusters 4-7) (Figure 2.18). This patient harbored a more diverse 
genotypes at the 1st time point: M41L, K103R, V106M, V179D, M184V, F227L (blue squares); 
K103R, V106M, V179D, M184V, F227L (green squares); M41L, K103R, V106M, V179D, 
M184V (brown squares) and M41L, V106M, V179D, M184V (black squares) compared to the 
2nd  time point which mainly harbored the wild type virus (orange squares) and those with the 
V106M (pink squares) and V179D (purple squares) mutations. This suggests that this patient was 
non-adherent thereby allowing the wild type variants to become the dominant strains.  
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Figure 2.18: Maximum likelihood (ML) trees of the HIV-1 pol region of PCSM004.The ML was 
constructed using the K81uf +I+G model of evolution selected by AIC implemented in the MODELTEST 
3.7. The scale bar at the bottom of the tree indicates the number of nucleotide substitutions per site. Red 
circles represent the sequences at the 1st time point while the green circles represent the sequences at the 
2nd time point. The squares represent the genotypes for the PR region. The intra sequence diversity and 
the standard error (SE) at the 1st and the 2nd time point and between the time points are represented in the 
table alongside the tree. The numbers the right-hand-side of tree represent the phylogenetic clusters. 
2.4.2.2 Phylogenetic analysis and intra sequence diversity of PCSM009 
PCSM009 also showed two distinct populations of sequences, one with the sequences at the 1st 
and the other with the sequences at the 2nd time point (Figure 2.19). The phylogenetic tree had 
eight clusters: four showing the sequences from the 1st time point (clusters 1-4) and four clusters 
showing the sequences from the 2nd time point (clusters 5-8). Clusters 1 and 2 had longer branch 
lengths compared to clusters 3 and 4. Clusters 5-8 showed short branch lengths of similar length 
with only a few sequences with longer branch lengths (in cluster 5-7). However, there are two 
sequences at the 2nd time point that form part of the cluster but also fall outside the cluster. This 
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could be possibly due to recombination. The intra sequence diversity at the 1st time point was 
0.8% (SE = 0.1 %) and decreased to 0.6% (SE = 0.1%) at the 2nd time point, while the diversity 
between the time point was high 1.9 % (SE =0.3%) (Figure 2.19).   
2.4.2.2. Phylogenetic analysis of PCSM009 investigating the evolution of RT resistance 
mutations at the 1st and the 2nd time point 
In this patient the sequences harboring the same resistance mutations clustered together (Figure 
2.14).  This patient harbored two genotypes at the 1st time point: D67N, K103E, V106M, E138K, 
M184V, G190A (blue squares) and K103E, V106M, E138K, M184V, G190A (green squares). 
The sequences at the 2nd time point were mostly wild type (orange squares) and with only two 
sequences with K103E, V106M, E138G, G190A (black squares) and the other with K103E, 
V106M, G190A (brown squares), with the variants with D67N, M184V, and E138K no longer 
detectable.  
 
Figure 2.19:  Maximum likelihood (ML) trees of the HIV-1 pol region of PCSM009. The ML was 
constructed using the TVM +I+G model of evolution selected by AIC implemented in the MODELTEST 
3.7. The scale bar at the bottom of the tree indicates the number of nucleotide substitutions per site. Red 
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circles represent the sequences at the 1st time point while the green circles represent the sequences at the 
2nd time point. The squares represent the genotypes for the PR region. The intra sequence diversity and 
the standard error (SE) at the 1st and the 2nd time point and between the time points are represented in the 
table alongside the tree. The numbers the right-hand-side of tree represent the phylogenetic clusters. 
 2.4.2.3 Phylogenetic analysis and intra sequence diversity of PCSM012 
In PCSM012, the phylogenetic tree had seven clusters: three showing the intermingling between 
the sequences at the 1st (red circles) and at the 2nd time point (green circles) (clusters 4, 5 and 7) 
and four clusters only with sequences from the 1st time point (1-3 and 6). Cluster 4, 5 and 7 had a 
diverse pattern characterized by short branch lengths at the 1st time point and by both short and 
longer branch lengths at the 2nd time point, suggesting less diversity at the 1st time point. Clusters 
1-3 and 6 showed short branch lengths with only a few sequences with longer branch lengths 
(clusters 3 and 6).  
The intra sequence diversity at the 1st time point was 1.0% (SE = 1.0%) and remained more or 
less the same at the 2nd time point: 1.1% (SE = 0.2%) (Figure 2.20), while the diversity between 
the time points was high: 1.3% (SE =0.2%).  
2.4.2.2 Phylogenetic analysis of PCSM012 investigating the evolution of RT resistance 
mutations at the 1st and the 2nd time point 
In this patient the majority of the sequences at the 1st  time point were wild type (orange squares) 
with a few sequences harboring the K103N (green squares) mutation and one sequence with 
V106M (brown) which intermingled with the K103N mutation at the 2nd  time point (Figure 
2.20a). The sequences at the 2nd time point harbored the K103N mutation with a few wild type 
viruses and one sequence with E138K mutation (black squares). Interestingly, all the sequences 
harbored only one of these mutations, suggesting independent selection of the viruses with each 
of the mutations. Collectively, the tree topologies of these patients were not only due to the effect 
of drug resistance mutations as the analysis of the trees where the drug resistance mutations were 
removed showed similar analysis (data not shown).  
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Figure 2.20: Maximum likelihood (ML) trees of the HIV-1 pol region of PCSM0012.The ML was 
constructed using the TVM +I+G model of evolution selected by AIC implemented in the MODELTEST 
3.7. The scale bar at the bottom of the tree indicates the number of nucleotide substitutions per site. Red 
circles represent the sequences at the 1st time point while the green circles represent the sequences at the 
2nd time point. The squares represent the genotypes for the PR region. The intra sequence diversity and 
the standard error (SE) at the 1st and the 2nd time point and between the time points are represented in the 
table alongside the tree. The numbers the right-hand-side of tree represent the phylogenetic clusters. 
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Figure 2.20A: Phylogenetic tree indicating the sub tree showing the sequences at the 1st time point 
harboring the K103N (green) mutation and two sequences with V106M (brown) which intermingled the 
K103N (green) mutation at the 2nd time point. 
2.6 Positive selection pressure 
The sequences of the two groups were then analyzed to investigate the sites under drug selection 
pressure. Analysis by the IFEL method showed that the positively selected sites were found 
mostly in the RT region in all the patients. More sites under positive selections were found in the 
patients that remained on 2nd line therapy compared to the patients that were switched from a 1st 
to 2nd line therapy. In the patients that remained on 2nd line therapy, ten sites were positively 
selected (Table 2.18). Of these sites, two were found at the PR positions (codons 10 and 76) 
(Table 2.18). These sites are associated with PIs resistance i.e. minor mutations L10F and major 
mutation L76V. Eight positively selected sites were found in RT positions (codons 57, 70, 103, 
135, 184, 286, 297 and 376) (Table 2.18). Of these sites, four sites were associated with RT 
resistance i.e. K70E/R/S, K103K/N/S/E, I135L/M/T and M184V. In addition, most of the sites 
under positive selection (60%) were found in putative CTL epitopes: PR codon 76 and RT 
codons 57, 135, 184, 297 and 397 (Table 2.18).  
In the patients that were switched from a 1st to 2nd line therapy, all five sites under positive 
selection pressure were in RT: codons 106, 173, 179, 210 and 272 (Table 2.3.5). Of these sites 
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two were associated with RTI resistance (V106M and V179D/E/F). All the sites under positive 
selective pressure were found at the putative CTL epitopes (Table 2.18). 
Table 2.18: Positive selection pressure HIV-1 pol region 
Patients that remained on 2nd line therapy  Patients that were switched from a 1st to 











PR-10 F/P -  - - - 
PR-76 V/L 68-76  - - - 
57 T/S 57-66  - - - 
RT-70 K/R -  - - - 
RT-103 K/S/N/E -  - - - 
    RT-106 V/M 105-113 
RT-135 I/V/T/M 127-135  - - - 
  -  RT-173 K/E/Q 173-183 
    RT-179 V/D/I 179-187 
RT-184 V/I/M 175-184   - - 
  -  RT-210 K/R 202-210 
  -  RT-272 P/A/S/P 269-277 
RT-285 T/A/V/I -  - - - 
RT-297 E/K 292-300  - - - 
RT-376 V/Q/L 374-383  - - - 
-Underline and bold indicate sites that are associated with drug resistance. 
2.7 Identification of signature differences within sequences at two time points.  
Signature differences between the sequences at the 1st and the 2nd time point were generated in 
VESPA using a 50% threshold (sequence difference were in > 50% of the sequences). In the 
patients that remained on 2nd line therapy, while there were individual differences between the 
time points, there were no common signature mutations seen. For PCSM001, the signature 
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difference was noted in one position i.e. codon position 201 which is at the RT position (Table 
2.19). For PCSM002, the signature difference was found at 1 PR position (codon 10) and at two 
RT positions (codon 233 and 301). For PCSM007, signature difference was found at six PR 
positions (codons 38, 45, 53, 70, 75 and 81) while three were found at the RT position (codon 
156, 345 and 395) suggesting that in this patient the genetic diversity was high at the PR region 
(Table 2.19). 
Table: 2.19: Signature differences positions of patients that remained on 2nd line therapy. 
 Signature difference 
AA Position PCSM001 PCSM002 PCSM007 
PR-10  L/F  
PR-38   Q/P 
PR-45   M/I 
PR-53   I/V 
PR-70   A/V 
PR-75   L/V 
PR-81   V/A 
RT-156   S/T 
RT-201 S/N   
RT-233  I/T  
RT-301  K/E  
RT-384   A/V 
RT-395   E/K 
 
For the patients that were switched from a 1st to 2nd line therapy, there were three signature 
differences that were common in RT: 200, 201 and 237 (Table 2.20). Overall, more signature 
differences was seen between the time points than in the patients that remained on 2nd therapy. 
For PCSM004, signature differences were found at 11 RT positions (codons 139, 200, 201, 204, 
237, 271, 277, 282, 312, 384 and 395). For PCSM009, this was noted at 2 PR positions (codon 
39 and 89) and 15 RT positions (codons 119, 135, 166, 200, 205, 237, 242, 265, 278, 289, 310, 
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336, 426, 433 and 455). For PCSM012, this was found at six RT positions (codon 125, 167, 201, 
272, 370 and 484).  
Table 2.20: Signature difference positions of patients that were switched from the 1st to 
the2nd line therapy.  
 Signature difference 
AA Position PCSM004 PCSM009 PCSM012 
PR-39   Q/P  
PR-89   L/M  
RT-119  R/K  
RT-125   S/T 
RT-135  E/A  
RT-139 L/M   
RT-166  N/D  
RT167   T/A 
RT-200 R/K E/K  
RT201 R/K  K/N 
RT-204 M/V   
RT-205  M/V  
RT-237 K/T K/E  
RT-241  I/V  
RT-265  K/R  
RT-271 A/V   
RT-272   K/E 
RT277 D/V   
RT-278  V/M  
RT-282 V/M   
RT-289  A/G  
RT-310  K/R  
RT-312 L/F   
RT-336  N/D  
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RT-370   S/A 
RT-384 A/T   
RT-395 E/A   
RT-426  A/V  
RT-433  D/N  
RT-455  H/Y  
RT-484   T/I 
-Underline and bold indicate signature differences that are common in the patients that are 
associated with drug resistance. 
2.8 Discussion  
The study of minority variants in HIV-1 infection is important as the impact of minority variants 
related to drug resistance on clinical outcomes remains unresolved although there is evidence 
that these minority variants can influence treatment efficacy. Detection of minority variants can 
assist in predicting the virological failure especially in the HIV-1 individuals that didn‘t have 
mutations detected by standard genotyping (Paredes i Deiros, 2009). Among the developed 
methods used to detect minority variants, cloning is one of the method that can allow the 
detection of minority variants to as low as ≥ 10 % of the viral population (Paredes i Deiros, 
2009).  
In this study, the minority variants in the HIV-1 Pol that were not detected by standard 
genotyping in patient failing HAART were assed using cloning. Different indicators of 
evolutionary forces were used to explain the evolution of the virus overtime, signature difference 
and putative sites under drug selection pressure. This also includes the phylogenetic analysis. 
First, the minority variants were identified at two time points in these patients. None of the 
patients that were switched from 1st to 2nd line therapy, which were studied to investigate the 
resistance profile before and after starting a PI inclusive regimen developed PI mutations when 
switched to PI inclusive regimen. This could be due to the high genetic barrier of PIs as the 
development of PI mutations takes time to develop (Charpentier et al., 2004) or it could be due to 
adherence. In PCSM004 and PCSM009 the additional NNRTI mutations detected at the 2nd line 
failure by cloning illustrate that these mutations can persist in the viral quasispecies after the 
drug exposure although at low frequencies. In PCSM009, the NNRTI mutations E138G (9%) 
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and E138K (91%) were detected by both methods at the 1st time point but only E138G was 
detected at the 2nd time point although the frequency was low (7%). This suggests that the 
mutation E138G was fit at the 2nd time point compared to E138K. PCSM012 had additional 
NRTI and NNRTI mutations at the 1st line failure detected by cloning also at low frequencies. 
Again, this suggests that this patient was not adherent therefore allowing the reemergence of the 
wild type viruses from the reservoir when they stop taking their treatment following the 
emergence of this drug resistance mutations (Hué et al., 2009).  
For the patients that remained on 2nd line therapy, which was studied to investigate the resistance 
profile with prolonged PI therapy, all the patients harbored both the major and the minor PI 
resistance mutations. There was an increase in the number and the frequency of the PI mutations 
and this could be attributed to the prolong time on a failing regimen. For PCSM001 the 
additional major mutation I47V was detected by cloning at the 1st time point, however the 
frequency was low (3%) suggesting that this variant might have been stored in the viral 
population and decayed to levels that cannot be detected by standard genotyping (Johnson and 
Geretti, 2010). In the same patient, the additional mutation I54L detected only by cloning in both 
time points and the detection of I54V only at the 1st time point by both methods suggests that at 
the 1st time point this mutations occurred as a mixture and due to the results of fitness cost i.e. 
high fitness cost of I54V, the mutation I54L was overgrown by I54V at the 2nd time point 
(Johnson et al., 2008). In PCSM001, the additional NNRTI mutations detected at the 1st line 
failure, again suggest that this patient was not adherent allowing these drug resistance mutations 
to decay to levels that cannot be detected by standard genotyping (Johnson and Geretti, 2010). In 
PCSM007, the detection of additional NNRTI mutations in both time points suggests that the 
detected mutations at the earlier time point persisted and could have contributed to treatment 
failure at the 2nd time point.  
Positive selection was the dominant selective force in the RT region in all the patients and more 
in the patients that remained on 2nd line therapy. The selection of these sites indicates that they 
increased viral fitness under drug selective pressure (Banke et al., 2009). Previous studies have 
suggested that the sites under positive selection also play a role in CTL response (Banke et al., 
2009). In this study, all the sites under positive selection in the patients that were switched from 
a 1st to 2nd line therapy were found in putative CTL epitopes. This suggests that these sites under 
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positive selection could also be involved in CTL response. Four novel sites (sites 57, 285, 297 
and 376) in the group that remained on 2nd line therapy and two novel sites (210 and 272) in the 
patients that were switched from the 1st to 2nd line therapy were detected in the RT region. The 
functional implication in positive selection at these sites is unknown; therefore these sites could 
be accessory mutations that improve the virus fitness rather than playing a role in drug resistance 
(Chen et al., 2004).  
Signature difference at the PR and RT in these groups was also characterized. Interestingly, the 
PR positions 10 (PCSM001) and 70 (PCSM007) that were positively selected were also a 
signature difference in these patients. This suggests that there was a drug selective pressure 
driving selection of these mutations at these sites (Huang et al., 2012). There was no signature 
difference at drug resistance positions in the patients that were switched from 1st to 2nd line 
therapy. This result adds to the study by Huang et al., 2012 where they also found no signature 
difference at drug resistance position. Thus the suggestion of these results on the evolution of 
drug resistance needs further study.  
Phylogenetic analysis was performed to investigate the evolution of the PR and the RT resistance 
mutations at the 1st and the 2nd time point. For most of the patients that remained on 2nd line 
therapy, there was intermingling between the sequences at the 1st and the 2nd   time point with the 
exception of PCSM007 where three clones from the 1st time point clustered with the sequences at 
the 2nd time point (Figure 2.16). This suggests that the sequences at the 2nd time point evolved 
from the sequences at the 1st point (Halvas et al., 2010). In contrast, there was no intermingling 
between the sequences at the 1st and the 2nd time point in the patients that were switched from 1st 
to 2nd line therapy except for PCSM012 which had a few sequences intermingling with the 
sequences at the 2nd time point. Similarly, the phylogenetic clusters specifically in the patients 
that remained on 2nd line therapy showed both the sequences from the 1st and the 2nd  time point 
while for the PI naïve patients, the phylogenetic clusters either showed sequences from the 1st  or 
2nd time point (Figure 2.13 and 2.14), except for PCSM0012. The tree topologies in each 
phylogenetic cluster could possibly be due to the presence of common drug resistant mutation 
and/or compensatory mutations that are associated with the increase in the viral fitness of the 
drug resistant virus (Hué et al., 2009). However, the presence of drug resistance mutations alone 
was not responsible for the tree topologies as the analysis of the trees where the drug resistance 
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mutations were removed showed similar results (data not shown). This result also adds to what 
has been reported by Kijak et al., 2002 and Bansode et al., 2011.  
The diverse pattern characterized by different branch lengths observed in the phylogenetic 
clusters could be the results of distinct evolutionary pressures within the virus such as positive 
selection (Fischer et al., 2012). Ideally, the sequences with less positive selection suggest that 
there is less diversity and the high positive selection suggest high diversity. Thus the difference 
in the branch lengths is not associated with viral fitness; only the drug resistance mutations are 
associated with viral fitness (Hué et al., 2009). Similarly, the distinct viral population of 
sequence, one with the sequences at the 1st time point and the other with the sequences at the 2nd 
time point observed in PCSM004 and PCSM009 could be due to the evolutionary pressures that 
occurred at each time point. 
Furthermore, the intra sequence diversity (genetic distances) in all the patients did not increase 
overtime and the overall diversity was low in all the isolates. However, the genetic diversity 
between the time points was higher than the genetic distances observed within the time points in 
all the isolates. Again, suggesting that the evolutionary pressure might have influenced this 
differences observed between the time points. 
The phylogenetic trees were further analyzed to assess the evolution of the RT and the PR 
resistance mutations at the 1st and the 2nd time point. This analysis showed a diverse pattern of 
genotypes in the RT and the PR region, specifically in the patients that remained on 2nd line 
therapy. The sequences harboring the same drug resistance mutations clustered together. There 
are several explanations for the presence of the different genotypes in each of the sequences. 
HIV-1 has a large diversity due to presence quasispecies (viral variants of related but distinctly 
different virus). This makes it possible for the selections of different genotypes in the sequences 
(Charpentier et al., 2004). In the patients that remained on 2nd line therapy, some of the 
genotypes were still detected at the 2nd time point with a few drug resistance mutations no longer 
detected. This finding could be due to fact that the time difference between the time points was 
short i.e. < 3 months thus no difference was seen over time. In the case of the patients that were 
switched from a 1st to 2nd line therapy, most of the drug resistance mutations detected at the 1st 
time point were not observed at the 2nd time point except for PCSM012 which had a few drug 
resistance mutation still detected at the 2nd time point. In this event, the drug resistant mutations 
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reverted back to the wild type at the 2nd time point. This indicates that the patients were not drugs 
thus the wild type viruses reemerged from the viral population after the emergence of drug 
resistance mutations that occurred while they were on treatment (Hué et al., 2009). Interestingly, 
these wild type viruses were not observed in a single cluster but rather in sub clusters. taking 
their This suggests that this viruses originated by reemergence of the several viral clones (Kijak 
et al., 2002). This findings also adds to what has been reported by other studies that in the ARV 
treated patients who stops taking their treatment, the wild type viruses may be reemerging from 
the original viral variants that had occurred before the drug resistant mutations emerge (Kijak et 
al., 2002). 
These findings that the patients that were switched from a 1st to 2nd line therapy (with the 
exception of PCSM012) showed the reemergence of the wild type at the 2nd  time point can also 
be explained by the different occurrence of these wild type viruses in different patients, related 
with the time since the patients were on treatment. The observation that the drug resistant 
mutations were not detected at the 2nd  time point shows that the fitness of the wild type viruses 
was higher at this time point (Kijak et al., 2002). In the case of PCSM012 at the 2nd time point, 
the sequences harboring the K103N mutation as those at the 1st time point coexisted with the 
sequences which were wild type. Again, this suggests that the wild type viruses at this time point 
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3.1 Introduction 
Detection of minority variants is important in clinical practice for effective treatment strategies. 
More sensitive methods which have been used to detect minority variants have shown that the 
preexisting minority variants that are not detect by standard genotyping can influence treatment 
efficacy both in treatment naïve and experienced patients (Avidor et al., 2013). In this study, 
minority variants were detected by cloning as described in chapter 2 and these minority variants 
were related to resistance to their 1st line regimen, especially among the patients that were 
switched from a 1st to 2nd line therapy. Thus these results are consistence with other studies that 
the minority variants that occur at low frequency of the HIV-1 viral population do contribute to 
treatment failure. However, the cloning method  have many disadvantages such as being 
extremely tedious, very expensive when trying to get a significant number of clones to detect 
minority variants to as low as 10 %  and time consuming (Avidor et al., 2013, Paredes i Deiros, 
2009, Ramirez et al., 2013).  
Ultra Deep Pyro-Sequencing (UDPS) has been shown to be more effective in detecting minority 
HIV-1 drug (Avidor et al., 2013). UDPS can overcome the disadvantages of clonal sequencing as 
it involves the direct clonal sequencing of mixed samples and resulting in more than 10000 reads 
per base (Ramirez et al., 2013). It is also less time consuming and its sensitivity to detect 
minority variants is higher compared to cloning (Ramirez et al., 2013). In this study, UDPS was 
performed to compare the drug resistance mutations detected by cloning and the standard 
genotyping.   
3.2. Materials and methods 
3.2.1 Generation of Amplicons for UDPS   
Amplicons were generated using a protocol for Amplicon Sequencing of HIV RT and PR yellow 
plate (Roche 454 life science). Briefly, the RNA was extracted from the plasma of samples using 
the QIAMP viral RNA mini kit (Qiagen) according to the kit protocol as described in Chapter 
2.2.3. Then the extracted RNA was stabilized using a 10 ng/µl of MS2 carrier RNA. The cDNA 
synthesis was performed in cDNA synthesis 96 well plate and the amplicon generation was 
performed with primers as described in the protocol (Roche 454 life science). 
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3.2.2 Amplification purification  
The PCR products were purified using the AMPure XP kit (Agencourt). Using a multi-channel 
pipette, 22.5 µl of the molecular grade water and 22.5 µl of the PCR products was added to each 
well on the 96 well plate according to the plate layout. The AMPURE beads bottle was mixed for 
30 seconds, 45 µl of the beads were added to each well and mixed at least 12 times. The plate 
was incubated at room temperature for 10 minutes. Then the plate was placed on a 96 well 
magnetic ring and incubated for 5 minutes at room temperature. After 5 minutes the supernatant 
was removed and discarded without disturbing the beads. Subsequently, the plate was removed 
from the 96 well magnetic ring and the beads were washed with 70% ethanol. The plate was 
placed back on the magnetic ring for 1 minute and the supernatant was removed again. The wash 
step was repeated.  After, the plate was placed back on the 96 magnetic ring stand and placed on 
a heat block set at 40 ˚C for 10 - 20 minutes. Ten µl of Tris Ethylediaminetet 
ethylenediaminetetraacetic acid (TE) was added to each well to elute the PCR products from the 
beads. The plate was incubated for 2 minutes and after the supernatant was transferred into a new 
96 well plate. The plate was covered with plate seal and stored at -20˚C until ready to be 
quantified.  
3.2.4 Amplicon Quantification  
The amplicons were quantified by flourometry using a Quant-it Pico Green dsDNA Assay kit 
(Invitrogen). Firstly, a DNA serial dilution standard was prepared. The DNA standard was 
thawed. 1 × TE was transferred to 1.5 microcentrifuge tube as follows: 441 µl TE to tube 1 while 
225 µl was transferred to tubes 2-8. Then a 50 × dilution was prepared by transferring 9 µl of 
DNA standard to tube 1 and vortex for 30 seconds. Subsequently, 225 µl from tube 1 was 
transferred to tube 2 and the serial dilution was completed by transferring 225 µl from tube to 
tube until to tube 7. Tube 8 served as a control DNA. One hundred µl of TE was transferred into 
each well of the 96 –well black flourometer.   
Using a multi-channel pipette, 99 µl of 1 × TE buffer was transferred to the remaining wells and 
1 µl of the DNA sample was transferred to each well containing the DNA sample. 100 µl of the 
diluted PicoGreen solution was added to each well and mixed by pipetting up and down. The 
flourometer plate was analyzed on the Glomax flourometer (Promega). The data was saved as an 
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excel file. The dilution was calculated using the rapid library calculator available on 
www.my454.com . This plots the standard curve and calculates the dilution volumes. 
 
 
Figure 3.1: Quantification of the amplicons using the fluorometry. www.my454.com  
All amplicons with a concentration ≤ 5 ng/µl were analyzed using the Agilent 2100 Bioanalyzer 
(Agilent Technologies) to further asses their quality. One µl of each purified amplicons were 
loaded on a DNA chip and then a DNA 1000 series II assay was run to quantify the PCR 
products with the required size. If the size of the band was ≥ 3:1 molar ratio relative to non – 
specific products, that amplicons was chosen and diluted according to the calculator and the 
amplicons were pooled equimolarly. 
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Figure 3.2: This is representative of the electrophoresis on the Agilent 2100 Bioanalyzer. Sample 2 
and 3 showed primer dimer at a size of ~100bp. Sample 5 showed primer dimer in primer B only. Sample 
4 didn‘t work due to insufficient amplicon.  
3.2.5 Amplicon pooling and dilution for emPCR amplification.  
After the dilutions and pools were prepared, 22.5 µl from the pool was transferred to a new well 
of the clean round bottom plate. 22.5 µl of the molecµlar grade water and 45 µl AMPure beads 
were added to the wells and mixed thoroughly by pitting up and down at least 12 times. The 
plate was incubated at room temperature for 10 minutes. The plate was then placed on the 96 
well magnetic ring stand and incubated for 5 minutes at room temperature. After 5 minutes, the 
supernatant was carefully removed. The plate was then removed from the magnetic ring stand 
and washed twice with 100 µl of freshly prepared 70% ethanol. The plate was then placed again 
on the magnetic ring stand and incubated for 1 minute and the supernatant removed. The 
washing step was repeated once more. The plate was then placed back on the magnetic ring stand 
and the pellet was dried at 40 ˚C on a heat block for 20 minutes. 22.5 µl of 1 ×TE was added to 
each well to elute the PCR product from the magnetic beads. The plate was then incubated for 2 
minutes while still on the magnetic ring. The purified PCR products (supernatant) was removed 
and transferred to 1.5 ml tube and stored at -20 ˚C. A further dilution of the intermediate pool of 
2 × 106 molecules was prepared by adding 1 µl of the 1 × 109 molecules to 499 µl TE in a 1.5ml 
tube and this final pool was stored was stored at – 20 ˚C.  
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3.2.6 Emulsion PCR amplification (emPCR). 
Emulsion PCR which is the emulsion based clonal amplification was performed using emPCR 
kit (Lib A) following the manufactures protocol (Roche, Applied Biosystem). Briefly, during the 
emPCR, 2.0 ml of 1 × Mock mix was added to the Turrax stirring tube containing the emulsion 
oil. The stirring tube was placed in the Ultra Turrax Tube Drive (UTTD) and run at 4000 rpm for 
5 min to mix the emulsion. The DNA library capture beads were prepared by adding 1 ml of the 
prepared 1 × wash buffer to each tube of the capture beads. The capture beads were placed in a 
bench top minifuge to pellet the capture beads. The supernatant was then removed. The capture 
beads were washed again with 1 ml of 1 × wash buffer and placed in a bench top minifuge to 
pellet. The amplicon DNA library to be amplified was thawed and the required volume was 




Therefore, 10 µl of DNA library was added to 30 µl of molecular grade water to make 0.5 copies 
of the DNA library bead. The DNA library bead was added to washed capture beads A and B. 
Six hundred µl of the Live Amp Mix A and B were added to the tube of the capture library A and 
B respectively and the mix transferred into the Turrax string tube and placed in the UTTD set at 
200 rpm for 5 minutes. One hundred µl of the emulsion reaction mix was transferred into a 96 
well plate and the plate was sealed. The plate was placed in the thermocycler and the 
amplification was carried out following this conditions: 
Temperature ˚C Time Cycles 
94 4 minutes 1 
94 30 seconds  50 
58 4.5 minutes  
68 30 seconds  
10 For hold  
 
2 molecules per bead × 5 million beads 
2 million molecules 
             5 µl of library = 
  93 
 
3.2.7   Bead washes and recovery  
The emulsion was aspirated from the plate into a 50 ml tube using GS Junior Titanium emPCR 
oil and breaking kit (Roche 454 life science). The plate was washed twice with 100 µl of 
isopropanol. Additionally, 5 ml of isopropanol was added to collect any beads that may remain 
in the tubing. For the bead recovery, the beads were washed several times using centrifugation to 
complete the breaking procedure (Roche 454 life science). 
3.2.8 DNA library and enrichment  
The enrichment beads tubes were vortex for 1 minute to resuspend its contents. The tubes were 
then placed in the Magnetic Particle Collector (MPC) and incubated for 3 minutes to pellet the 
enrichment beads and the supernatant removed. 500 µl of the enhancing buffer was added to the 
enrichment bead and pellet the enrichment beads using an MPC. The latter step was repeated 
once more. The beads were resuspended in 80 µl of the enhancing buffer and vortex. 
During the enrichment of the DNA carrying beads, 80 µl of washed enrichment beads were 
mixed with DNA beads and placed on the rotator at room temperature for 5 minutes. The tube 
was placed in the MPC for 3-5 minutes to pellet the enrichment beads and the supernantant 
removed. The beads were then washed 6 to 10 times with 1ml of enhancing buffer and the tubes 
were placed into the MPC to pellet the beads and the supernatant removed.  
Following this, the collection of the beads was done as follows: the tube of the enriched beads 
was removed from the MPC and resuspended in 700 µl of melt solution, vortex for 5 seconds 
and placed again in the MPC to pellet the beads. The supernatant containing the enriched DNA 
beads was transferred into a new 1.7 ml and resuspended once again with 700 µl of melt solution 
and the supernatant transferred to same tube. The DNA beads were then washed with 1 ml of the 
annealing buffer and vortex for 5 seconds, spin- rotate-spin and the supernatant was discarded. 
This washing step was repeated two times. Finally, 100 µl of the annealing buffer was added to 
the beads and vortex.  
For the sequencing primer annealing, 15 µl of Seq Primer A and Primer B were added to the 
DNA capture beads, vortex and the tube was placed in a heat block at 65 ˚C for 5 minutes and 
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subsequently cooled on ice for 2 minutes. The beads were then washed twice with 1 ml 
annealing buffer, vortex for 5 seconds and spin-rotate-spin and the supernatant was removed.   
The amount of enriched beads was evaluated using the GS junior beads counter. According to 
the kit protocol the recommended input bead number for UDPS is 500, 000 enriched DNA beads 
(Avidor et al., 2013). 
3.2.9 Ultra deep pyro sequencing (UDPS).  
The UDPS was performed using the GS Junior Titanium sequencing kit together with the 
matching GS junior Titanum PicoTiterPlate (PTP) kit following the kits protocol (Roche 454 life 
science). Briefly, the initial steps involved in the GS junior sequencing procedure includes the 
pre wash of the GS junior instruments with pre wash buffer, washing step of the PTP plate with 
the Bead Buffer 2 (BB2). Four bead layers were prepared: Enzyme bead pre-layer, DNA and 
packing beads, enzyme beads post layer and the PPiase Beads. Firstly, an aliquot of the enriched 
DNA beads was mixed with 6 µl of the control beads XLTF and 500 µl of BB2 was added to the 
beads, vortex briefly and incubated for 20 minutes at room temperature on the lab rator. While 
waiting for the 20 minutes, the packing beads, enzyme beads post layer were washed three times 
with 1 ml with BB2 and centrifuge at 9.300 RCF for 5 minutes for each wash. 175 µl of packing 
beads were added to DNA mixture containing the polymerase, polymerase cofactor and BB2, 
vortex at low speed and incubated on the lab rotator at room temperature for 5 minutes. The PTP 
was loaded first with 350 µl of the bead suspension (enzyme bead pre layer) and this was 
centrifuge for 5 minutes at 1, 620 RCF. After 5 minutes the supernatant was removed and 350 µl 
of the second layer was loaded to the PTP. This was centrifuge for 10 minutes at 1.6220 RCF. 
Again after 10 minutes the supernatant was removed and the enzyme post layer was loaded and 
then centrifuge at 1,620 RCF for 10 minutes. After centrifugation, the supernatant was removed 
and subsequently 350 µl of the last layer (PPiase beads) was loaded to the plate and centrifuged 
in BDD for 5 minutes at 1,620 RCF. Finally, the reagent cassettes were loaded onto the GS 
junior instrument, the PTP plate was loaded and the sequencing programme started.  
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3.2.10 Data analysis  
The sequence analysis was performed using the Amplicon Variant GS Amplicon Variant (AVA) 
software (Roche 454 life science). Briefly, the AVA software detects and quantitates the known 
variants as well as the novel DNA variants. It computes the alignment of the read sequences and 
identifies variation between the reads and the reference sequence. The identified variants are 
represented by histograms that shows the variant position and multiple alignments that are color 
coded highlighting the regions and bases that are different from the reference sequence (Figure 
3.3 and 3.4).    
 
Figure 3.3: The GS junior Amplicon variant analyzer showing the base substitution point that is 
different from the reference sequence. The top graph shows the mutation frequency of the sample. 
www.roche-biochem. 3/03/2014.    
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Figure 3.4: GS junior Amplicon variant analyzer showing multiple alignments. The top graph 
represents the reference sequence, the 2nd  graph represent the difference between the reference sequence 
and the sample sequences while the 3rd  graph shows the difference between the two graph above such 
that if the sample sequences is the same as the reference sequence the histogram bar height is zero. 
Source: (Roche 454 life science, www.roche-biochem.jp)     
This AVA software therefore assigns each read to the proper amplicon and patient sample. It also 
aligns the generated sequences and reports the frequency of identified drug resistance mutations 
in a summary table according to the international AIDS Society USA (ISA-USA) and the 
Stanford algorithm (Avidor et al., 2013). Using the AVA project manager, a data file of the 
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3.3 Results  
The patients that were switched from a 1st to 2nd line therapy were selected for UDPS because 
they had no PI resistance mutations detected by standard genotyping and cloning when they were 
switched from a 1st line to 2nd line therapy.  
Despite considerable effort in performing UDPS for HIV RT and PR, PCR amplification was not 
successful for all the DNA samples. For PCSM004, only the 2nd time point PCR amplification 
was successful while for PCSM009 and PCSM012 the amplicons from both time points were 
successfully sequenced. Although amplification was successful for PCSM012 in both time 
points, sequence of the 1st time point amplicon was unsuccessful.  
In all the samples, most of the minority variants that were detected by UDPS were also detected 
by cloning (Table 3.1- 3.3). For PCSM004, at the 2nd time point, UDPS detected two additional 
minority variants that were not detected by cloning: NRTI mutations K65N and K65R with a 
frequency of 2.32 % and 0.73% respectively. The NNRTI mutation V179D which was detected 
by cloning was also detected by UDPS but the frequency was low (1.54%) compared to the one 
detected buy cloning (14%) (Table 3.1). No drug resistance mutations were detected in PR at this 
time point for both cloning as well as UDPS. However, the only mutation detected in PR was 
L10Y which is described as being a non-polymorphic accessory PI mutation (Table 3.1).  
Tables 3.1-3.3 shows the comparison of the mutations detected by the three methods used in this 
study i.e. Standard genotyping, Cloning and UDPS. The red marked mutations shows additional 
mutations detected by cloning as described in chapter 2 (Tables 2.12- 2.14) while the blue 
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Table 3.1: Comparison of mutations detected by standard genotyping, cloning and UDPS for 
PCSM004. The red marked mutations are additional mutations detected by Cloning while the 
blue marked mutations are additional mutations detected by UDPS.  
Mutations Mutations detected 
by standard 
genotyping 
Frequency (%) of 
mutations  detected 
by cloning 
Frequency (%) of 
































p-L10Y  no no  0 0  NA 0.21 
NRTI          
M41L  yes no  73 0  NA 0 
K65R  no no  0 0  NA 2.32 
K65N  no no  0 0  NA 0.73 
M184V  yes no  97 0  NA 0 
NNRTI          
K103R  yes no  93 0  NA 0 
V106M  yes no  97 4  NA 0 
V179D  yes no  97 14  NA 1.54 
F227L  yes no  33 0  NA 0 
*NA- not applicable 
For PCSM009, again the minority variants that were detected by UDPS were also detected by 
cloning (Table 3.2). At the 1st time point, the RT drug resistance detected by all the methods 
included major NRTI mutations D67N and M184V and NNRTI mutations K101E, V106M, 
E138G/K and G190A. The frequencies of these mutations were very similar in both methods 
(Table 3.2). The additional RT mutations detected by UDPS included the NRTI mutations K65R 
(0.65 %), and the NNRTI mutation F227L (16.68%) (Table 3.2). At the 2nd time point, the NRTI 
mutations D67G, D67N, K65R, and NNRTI mutations K101E, V106M, E138G, E138K, G190A 
and F227L were also detected by UDPS. The frequencies of these mutations decreased at this 
time point but they were higher compared to the frequencies detected by cloning (Table 3.2).  
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Again, no major mutations were detected in PR at either time points for both cloning and UDPS. 
However, accessory mutation A71T (1.19%), was detected at this time point by UDPS.  
Table 3.2: Comparison of mutations detected by standard genotyping, cloning and UDPS for 
PCSM009. The red marked mutations are additional mutations detected by Cloning while the 
blue marked mutations are additional mutations detected by UDPS. 
Mutations Mutations detected by 
standard genotyping 
Frequency (%) of 
mutations detected by  
Cloning 
Frequency (%) of 
mutations  detected 
by UDPS 














p-A71T no no 0 0  0 1.19 
NRTI        
D67G no no 0 3  0 0.24 
D67N yes no 65 0  0 0.53 
K65R no no 0 0  0.64 0.75 
M184V yes no 100 0  99.8 0 
NNRTI        
K101E yes no 100 10  92.07 24.54 
V106M yes no 100 10  100 24.61 
E138G yes no 9 7  4.19 24.79 
E138K yes no 91 0  87.88 0.46 
G190A yes no 100 10  99.85 98.08 
F227L no no 0 0  16.68 1.8 
p-A98S no no 0 0  0 0.46 
p- V90I no no 0 0  0 0.14 
p-V179I no no 0 0  4.63 2.06 
 
For PCSM012, the minority variants detected by cloning at the 1st time point were also detected 
at the 2nd time point by UDPS (Table 3.3). The RT drug resistance mutations included the NRTI 
mutation T69A and the NNRTI mutations K103N, V106M, E138K and G190A. V106M, E138K 
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and G190A were only detected by UDPS at the 2nd time point. For mutations T69A and K103N, 
the frequency was low compared to the frequency detected by cloning. For cloning, the 
frequency for T69A was 62% while for UDPS it was 24.95%. For the mutation K103N, 
frequency detected by cloning was 66% by cloning while for UDPS it was 25.13% (Table 3.3). 
Table 3.3: Comparison of mutations detected by standard genotyping, cloning and UDPS for 
PCSM012. The red marked mutations are additional mutations detected by Cloning while the 
blue marked mutations are additional mutations detected by UDPS. 
Mutations  Mutations detected 
by Standard 
genotyping 
Frequency (%) of 
mutations  detected by  
Cloning 
Frequency (%) of 
mutations  detected 
UDPS 














- no no  0 0 NA 0 
NRTI        
T69A no no  14 62 NA 24.95 
T69D no yes  0 0 NA 0 
NNRTI        
K103N yes yes  26 66 NA 25.13 
V106M no no  9 0 NA 24.61 
E138K no no  3 0 NA 24.79 
G190A no no  3 0 NA 0.46 
*NA- not applicable 
In addition, to analyze the mean number of minority drug resistance mutations detected 
specifically by cloning and UDPS, a paired student Test using Graph Pad prism was done. This 
analysis was performed on the drug resistance mutations detected at the 2nd time point as the 
samples at the 1st time point was not successful for all the samples. The mean number of 
difference of mutations between the methods was 2.667 with 95 % CI -1.128- 6.461. The 
differences in mutations detected per drug class are shown in Figure 3.1. 
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Figure 3.5 Mean number of drug resistance mutations (Drug class) detected by cloning and UDPS. 
In addition, one sample from the patients that remained on 2nd line therapy (PCSM007) was also 
sequenced by UDPS as described above. This was the only sample available from this group and 
only the 1st time point sample was available for sequencing.  
In this patient, at this time point, the PR drug resistance mutations detected by all the methods 
included L10F, M46I, I54V and V82A. The frequency of this mutations detected by UDPS was 
high compared to the frequency detected by cloning (Table 3.4). No additional PR mutations 
were detected by UDPS at this time point. The RT mutations detected by all the methods 
included the NRTI mutations D67N, M184V and NNRTI mutations K103N and V106M. The 
frequency detected by UDPS for the mutation D67N was low (91.87%) compared to the 
frequency detected by cloning (96%) while the frequency for M184V was high (97.42 %) 
compared to the frequency detected by cloning (43%). For the mutation K103N, the frequency 
detected by cloning was 93 % while for the UDPS it was 97.71%. For the mutation V106M, the 
frequency detected by cloning (99.42%) and UDPS (100%) were very similar (Table 3.4).   
Additional RT mutations (blue marked mutations) detected by UDPS included the NRTI 
mutation K65R (0.75%), accessory mutations F77L (0.75%), V75I (0.23%) and major NNRTI 
mutation K103S (1.3%) (Table 3.4). However, some of the mutations that were detected by 
standard genotyping and additional mutations detected by cloning were not detected by UDPS. 
This includes the PR mutations K20R, A71V, L76V, NRTI mutations K70R and NNRTI 
mutations K101E, E138K, G190A (Table 3.4).  
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Table 3.4: Comparison of mutations detected by standard genotyping, cloning and UDPS for 
PCSM007. The red marked mutations are additional mutations detected by Cloning while the 
blue marked mutations are additional mutations detected by UDPS. 
Mutations Mutations detected 
by standard 
genotyping 
Frequency (%) of 
mutations  detected by 
cloning 
Frequency (%) of 


























L10F yes yes 57 82 86.78 NA 
K20R no no 50 18 0 NA 
M46I yes yes 87 96 97.7 NA 
I54V yes yes 87 18 100 NA 
A71V yes yes 50 79 0 NA 
L76V yes yes 50 89 0 NA 
V82A yes yes 87 96 100 NA 
NRTI       
D67N  yes yes 96 96 91.87 NA 
K65R no no 0 0 0.75 NA 
K70R no no 53 14 0 NA 
V75I no no 0 0 0.23 NA 
F77L no no 0 0 0.34 NA 
M184V yes no 43 14 97.42 NA 
NNRTI       
K101E no no 0 57 0 NA 
K103N yes yes 93 96 97.71 NA 
K103S no no 0 0 1.3 NA 
V106M yes yes 100 96 99.42 NA 
E138K no no 14 57 0 NA 
G190A no no 14 57 0 NA 
F227L no no 0 0 0.34 NA 
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3.4 Discussion  
HIV-1 drug resistance testing has been based on standard genotyping and the detection limitation 
of standard genotyping is that it detects mutations >20% of the viral population but not the 
minority variants which occur at low levels of the viral population (Charpentier et al., 2004). To 
overcome this, more sensitive methods have been developed to detect minority variants (Paredes 
i Deiros, 2009). In the previous chapter, cloning, which has a sensitivity of >10% in detecting 
minority variants (Paredes i Deiros, 2009), was used to described resistance mutations. A newly 
developed method, UDPS is now being used to detect minority variants as an alternative to 
cloning. UDPS is more sensitive than cloning in detecting minority variants and it has a 
sensitivity of 0.5-1% (Paredes i Deiros, 2009). In this chapter the minority variants detected by 
UDPS are compared to those detected by cloning and standard genotyping.  
Recent studies applying this method have found that UDPS identified a significantly larger 
proportion of minority variants compared to standard genotyping and these minority variants 
increased the risk of virological failure (Simen et al., 2009). In another study by Le et al., 2009, 
they compared standard genotyping and UDPS in treatment experienced patients, they found that 
minority variants were detected in all the patients by UDPS and non by standard genotyping and 
also these minority variants correlated with virological failure. In addition they stated that 
additional minority variants increased the patients‘ resistance to at least one or two ARVs (Le et 
al., 2009).  
In this study, samples from the 2nd time point of the patients that were switched from a 1st to 2nd 
line therapy were sequenced by UDPS, and where available. This group was of particular 
interest, as these patients were switched from their 1st line regimen (PI naive) to their 2nd line 
regimen (PI inclusive), allowing us to investigate the presence of baseline minority PI mutations, 
as well as the development of minority PI mutations once on the PI. However, no mutations were 
detected, even using UDPS in these patients, suggesting that this patients might have poor 
adherent to PI regimen or they required more time to develop PI mutations as the development of 
PI resistance is a gradual process and require more mutations to be resistance to PI (Charpentier 
et al., 2004, Shafer, 2002). 
UDPS did detect additional NRTI mutations (D67G, D67N and K65R) when compared to 
cloning, but this difference was not significant. Only one isolate was sequenced from the patients 
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that remained on 2nd line therapy. Here, additional NRTI mutations were detected (K65R, V75I 
and F77L). No additional PI mutations were detected; this could be likely due to that more time 
was required for development of additional PI mutations as these results were from the 1st time 
point.  
Interestingly, the K65R mutation, which causes resistance to NNRTIs abacavir (ABC), 
didanosine (ddi), emtricibine (FTC), lamivudine (3TC), tenofovir (TDF) and low level to 
stavudine (d4T), was found at low levels in 3 isolates (0.75.% - 2.32 %). This mutation has been 
strongly related with the development of virological failure in Subtype C infected individuals 
(Bansode et al., 2013, Fischer et al., 2012). It has been reported that in HIV subtype C, the RT 
KKK nucleotide motif at codons 64-66 seems to results to template pausing that increase the 
selection of K65R (Recordon-Pinson et al., 2012). However, K65R mutation has been reported 
to be an UDPS artifact due to PCR errors occurring at this position. This error depends on the 
template codon in the encoding nucleotide sequence (64 -66) of the RT gene which is different 
among subtypes B and C (Bansode et al., 2013, Fischer et al., 2012). In Subtype C the encoding 
nucleotide sequence is either AAA-AAG-AAG or AAA-AAG-AAA while for subtype B is 
either AAG-AAA-AAA or AAG-AAA-AAG (Fischer et al., 2012). To prevent this error from 
occurring, a high fidelity enzyme was used in the amplicon generation.  
In the group that was switched from a 1st to 2nd line therapy, UDPS also detected additional 
NNRTI variants in two patients (PCSM004 and PCSM012) with at a higher frequency than 
cloning. In contrast, the additional NNRTI variants (K103S and F227L) detected in PCSM007 
was low and they were not detected by cloning.   
In a study where they were comparing the minority variants detected by cloning and UDPS, as 
expected UDPS yielded more mutations than cloning (Ramirez et al., 2013) but they also stated 
that cloning included insertions and deletions which was not detected by UDPS (Ramirez et al., 
2013). In contrast, in a study by Lanier et al., 2007 where they also compared UDPS and cloning 
found out that UDPS yield similar data to cloning and their frequency was not significantly 
different. Both methods showed low levels of L74V and K65R. This finding is consistence with 
the results we found in this study. Almost all the mutations found by UDPS were also detected 
by cloning and the frequency of some of the minority variants detected by both methods was 
very similar. However, some of the minority variants detected by UDPS had a low frequency 
  105 
 
compared to cloning. This could be due to that the depth of coverage at those variant positions 
was low.  
There are many factors that could contribute to the detections of minority variants by UDPS. 
This could be due to the resistant viral population decaying to levels that cannot be detected by 
cloning and standard genotyping in the absence of drug pressure (Fischer et al., 2012). This 
usually applies to the patients with poor adherence allowing resistance variants not to reach the 
threshold (Fischer et al., 2012). This is also seen in our patients that were switched from their 1st 
to 2nd line therapy that were investigated. We expected UDPS to detect mutations in the PR 
region other than the accessory mutations, but this was not the case. This suggests that these 
patients were not adherent.  
In other studies where they were also investigating the minority variants in patients who were 
switched to 2nd line therapy, UDPS did detect minority variants at 2nd line failure (Fischer et al., 
2012). Based on their results they stated that UDPS may be a better approach in detecting the 
development of PI resistance before it become fixed in the viral population (Fischer et al., 2012). 
It has been suggested that most of the minority variants would first occur as a single variant and 
would represent the first step in the development of PI resistance. However, more mutations 
would be required to develop PI resistance (Charpentier et al., 2004, Fischer et al., 2012, Shafer, 
2002). In patients with poor adherence the wild type viruses are favored and the resistant variants 
are less fit in the absence of drug selective pressure. This also explains the absence of PI 
resistance by both UDPS and cloning which could be due to poor adherence to PI regimens in 
our cohort. In addition, it is challenging to investigate the evolution of PI resistance as it would 
require several time points to study the multiple pathways to resistance, as PI resistance is a 
gradual process and it has a high genetic barrier (Charpentier et al., 2004, Fischer et al., 2012, 
Shafer, 2002). Therefore to achieve this, a large number of samples of patients failing PI therapy 
would be advantageous.  
The limitations of this study include the small sample size, as only 3 patients from the patients 
that were switched from a 1st to 2nd line therapy were available for UDPS and only the samples at 
the 2nd time point were available for two patients (PCSM004 and PCSM012). In addition, one 
sample from the patients that remained on 2nd line therapy was sequenced and also with only one 
time point available (1st time point). It would have been informative if UDPS was performed in 
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all the samples in both time points. Secondly, UDPS is very expensive and therefore, samples 
that failed during the sequencing were not repeated. Thirdly, UDPS is also subjected to PCR and 
sequencing artifacts which may affect its specificity for example in the case of the detection of 
mutation K65R which is likely to be PCR artifact (Fischer et al., 2012).  
Finally, while UDPS is expensive, cloning is very time consuming, as well as expensive when 
trying to get a significant number of clones to detect minority variants to as low as 10 % (Paredes 
i Deiros, 2009). Therefore, UDPS would be a valuable tool for resistance genotyping, especially 
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4.1 Introduction  
HIV PR is responsible for the formation of enzymes and proteins of the mature virus through the 
process of post translational processing of the viral Gag and Gag-pol (Clavel and Mammano, 
2010).  The development of PI resistance is generally thought to be a gradual process and the 
increase in the level of resistance requires the presence of many mutations in the gene itself 
(Charpentier et al., 2004, Shafer, 2002). Resistance mutations that causes changes in the PR has 
also been shown to decrease the viral replication capacity due to decreased processing of the PR 
natural substrate (Dam et al., 2009). Apart from the mutations directly affecting the PR, gag 
mutations have been reported to contribute to the development of PI resistance (Clavel and 
Mammano, 2010, Dam et al., 2009). Many studies have shown that gag mutations can also 
contribute to PI resistance in the absence of PR mutations and mostly this was observed in the 
protease cleavage site (CS) (Ghosn et al., 2011, Nijhuis et al., 2007).  
In this study, to further investigate the contribution of gag mutations to protease inhibitor 
resistance the gag-protease region of the patients that were genotyped at 1st line failure (1st time 
point), as well as at 2nd line failure (2nd time point) and those that were genotyped at 2nd  line 
failure only (both time points) was sequenced and analyzed.    
4.2. Materials and methods 
4.2.1 RNA extraction from plasma sample.  
RNA was extracted from the plasma of samples using the QIAMP viral RNA mini kit (Qiagen) 
according to the manufactures protocol (Chapter 2.2.3). RNA was stored at -80C until used.  
4.2.2 Reverse transcription and amplification of HIV Gag –protease. 
Reverse transcription (RT –PCR) was performed using a superscript III one step RT PCR kit 
(Invitrogen, life technologies). For the 1st  round PCR, primers Gag+1 and 3‘ rvp were used 
while for the 2nd   round PCR, 100- mer forward and reverse were used (Wright et al., 2010). The 
primers for the 1st round are shown in the table below: 
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Table 4.1: The HXB2 position and primers used to amplify the gag region.   
Primer name HXB2 position Primer sequence 
Gag+1 (10uM) 
 
675- 697 F GAGGAGATCTCTCGACGCAGGAC 
3'rvp (10uM) 2725- 2696 R GGAGTGTTATATGGATTTTCAGGCCCAATT 
 
The Primers used for the 2nd round were as follows: 
 1. Forward primer 
ACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTAC
GCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGG 
2. Reverse primer  
GGCCCAATTTTTGAAATTTTTCCTTCCTTTTCCATTTCTGTACAAATTTCTACTAAT 
GCTTTTATTTTTTCTTCTGTCAATGGCCATTGTTTAACTTTTG    
The RT mix was prepared in the master mix room. The 2 × reaction mix buffer and primers, 
were thawed and vortexed for 5 seconds. The enzyme superscript III was not vortexed. Care was 
taken to be quick when preparing the RT PCR master mix for the 1st round as superscript III is 
unstable at room temperature. The RT master mix was prepared in a 1.5 ml micro centrifuge as 
follows:  
Reagents Volume (µl) Final concentration 
2 × Reaction mix buffer 12.5 × 1 
Gag +1 (10µM) 0.5 0.2 Um 
3rvp (10µM) 0.5 0.2µM 
DEPC 3 - 
Superscript ΙΙΙ (200U/µl) 1 4U/µl 
RNA template 7.5 - 
Total 25  
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A volume of 17.5 µl was added to the labeled 0.2 ml reaction tube 7.5 µl of RNA was added and 
mixed properly. The conditions for the 1st round PCR product were as follows: 
Temperature ˚C Time Cycles 
55 30 minutes 1 
94 2 minutes 1 
94 15 seconds 35 
55 30 seconds  
68 2 minutes  
68 5 minutes 1 
4 Hold  
 
The master mix for the 2nd round PCR product was prepared as follows:  
Reagents Volume (µl) Final concentration 
DEPC 37 - 
10 × Taq Buffer 5 × 
dNTPs (2.5mM) 4 0.2µM 
Forward long primer 
(10µM) 
0.8 0.16µM 
Reverse long primer (10µM) 0.8 0.16µM 
Ex taq (250U) 0.25 1.25U/µl 
1st round PCR product 2 - 
Final volume 49.85  
 
A volume 47.8 µl of PCR master mix was added to each labeled 0.2 ml tube and 2 µl of the 1st 
round PCR product was added to the tubes. The PCR was run on thermocycler using the 
following condition:  
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Temperature ˚C Time Cycles 
99 2 minutes 1 
94 30 seconds 40 
60 30 seconds  
72 2 minutes  
72 7 minutes 1 
4 Hold  
 
4.2.3 Amplicon purification and quantification  
The PCR products were purified using a Qiagen PCR clean up kit following the manufacturer‘s 
instructions (Qiagen) as described in Chapter 2.2.2. The PCR products were quantified by gel 
electrophoresis using a low DNA mass ladder to determine the concentration of the PCR 
products (Figure 4.1).  
  
        
Figure 4.1 An Agarose gel electrophoresis after the PCR cleanup.  The Low DNA mass ladder (left) 
shows the amount of DNA fragment in ng. The size of the PCR product is approximately 1.5 kb. 
4.2.4 Sequencing of the PCR products 
The PCR products were diluted to 2 ng/µl which is an optimal concentration for sequencing of 
PCR products. The HXB2 position and sequences of the 5 primers used for the sequencing of the 
protease-gag region are represented in the table below:  
       100  
       60  
         40  
         20 
PCR product 
1.5 kb 
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Table 4.2:  The HXB2 position and primers used to sequence the gag region.  
Primer name HXB2 Position Primer Sequence 
SQ2FC 991- 1010 CTTCAGACAGGAACAGAGGA 
GF100 1817- 1834 TAG AAG AAA TGA TGA CAG 
SQ16RC 1098- 1078 CTTGTCTAGGGCTTCCTTGGT 
GAS4R 1481- 1462 GGTTCTCTCATCTGGCCTGG 
GR1981 1981- 1960 CCT TGC CAC AGT TGA AAC ATT T 
 
Sequencing was carried out as described in chapter 2.2.7 expect that the master mix for each 
primer was prepared as follows: 
Reagents  Volume (µl) Final concentration 
Big Dye ready reaction mix 0.4 - 
5×sequencing buffer  2 1× 
Primer (3.2 pmol/µl) 1 0.32 pmol/µl 
Water  1.6 - 
Final Volume  5 - 
 
The sequencing was set up in a micro Amp optical 96 well reaction plates as described in chapter 
2.2.7, except that a volume of 5 µl of each reaction primer mix was added to the selected well 
and of 5 µl of diluted PCR product. 
4.2.5 DNA Sequence analysis  
Sequence analysis was done as described in chapter 2.2.8. The gag-protease mutations were 
analyzed based on literature studies and those mutations that have been reported to be associated 
with drug resistance. This includes the V35I, G123E, H219Q, G381S, V390I, A431V, L449P, 
and P453L (Fun et al., 2012, Gatanaga et al., 2002, McKinnon et al., 2011). 
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4.2.6 Statistical analysis  
The correlation between the PR and gag mutations was determined using the spearman rank 
order correlation using the GraphPad Prism 6. 
4.3 Results  
In order to investigate the contribution of gag mutations to protease inhibitor resistance in these 
patients, the gag-protease gene was analyzed.  
4.3.1 Mutations occurring in the gag-protease region in patients that were switched from a 
1st to 2nd line therapy. 
None of these patients that were switched from a 1st to 2nd line therapy harbored mutations in the 
PR region. However gag mutations V35I, G123E, H219Q and gag cleavage site (CS) mutation 
G381S were detected in some of these patients (Table 4.1).  
For PCSM004, at the 1st time point, two gag mutations were observed: mutations G123E and 
V35I which are located at the MA/p17. These mutations are associated with drug resistance 
(Gatanaga et al., 2002). However these mutations are rarely described in the literature. After nine 
months, a 2nd genotype was performed and the gag mutations that were detected at the 1st time 
point were still detected with no additional mutations in gag. 
 
For PCSM009, at the 1st time point the mutations G123E located at the MA/p17, H219Q at the 
capsid (CA)/p24 and CS mutation G381S were detected. Again these mutations are associated 
with drug resistance (Gatanaga et al., 2002). After twelve months, a 2nd genotype was performed. 
Again, the gag mutations that were detected at the 1st time point were still detected. Interestingly, 
this patient had no PI mutations in both time points but harbored H219Q at the 1st and 2nd time 
point and it has been reported that this mutation is selected during PI exposure (Fun et al., 2012). 
This suggests that this mutation also play a role in PI resistance even in the absence of PI 
resistance mutations (Ghosn et al., 2011, Nijhuis et al., 2007).  
 
For PCSM012, at the 1st time point only the gag CS mutation G318S was observed. Again this 
mutation is associated with drug resistance (Gatanaga et al., 2002) but it has been rarely 
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described in the literature. After eight months, a 2nd genotype was performed. Again for these 
patients, the gag mutations that were detected at the 1st time point were still detected. 
Table 4.3 Mutations occurring in the gag and PR of patients that were switched from a 1st 
to 2nd line therapy.  
Patient  PR mutations  Gag mutations 
    1st  time point 2nd  time point 1st  time point 2nd time point 
PCSM004    None None G123E, V35I G123E,V35I 




PCSM012    None None G381S G381S 
 
4.3.2 Mutations occurring in the gag-protease region in patients that remained on 2nd line 
therapy.  
All these patients had several gag and PR mutations. The most common gag mutations found in 
all the patients is A431V, located at the NC/p1 CS. This is consistent with other reports (Fun et 
al., 2012).  
For PSCM001, at the 1st time point the gag mutations that were detected included the gag CS 
mutations G381S, A431V, L449P and P453L. Mutations L449P and P453L are located at the 
p1/p6 CS and have also been described to have an impact on PI resistance (Fun et al., 2012). 
Some of these mutations are observed in the presence of specific PR mutations: mutations 
A431V, L449P and P453L occurred in the presence of mutations M46I, V82A and I84V (Table 
4.2). This suggests that these mutations appear in the presence of PR mutations thus they serve as 
compensatory mutations to PI resistance (Nijhuis et al., 2007, Roquebert et al., 2006a). The gag 
CS mutation G381S has been reported to be associated with drug resistance but its role it unclear 
(Gatanaga et al., 2002). However, since we also found this mutation in the patients that were 
switched from the 1st line to the 2nd line therapy, this suggests that it is not selected for by PIs. 
After one month, a 2nd genotype was performed; the gag mutations that were detected at the 1st 
time point were still detected with no additional mutations in gag.  
  115 
 
For PSCM002, at the 1st time point the gag mutations that were observed were G123E, V390I 
(McKinnon et al., 2011) and gag CS mutation G381S. Again, although these mutations have 
been rarely described they are associated with PI resistance (Fun et al., 2012, McKinnon et al., 
2011). These mutations can appear in the absence of PR mutations selected under PI exposure. 
After two months, a 2nd genotype was performed. The mutations G123E, G318S and V390I were 
still detected and during this time point additional mutations A431V and P453L were detected. 
Again, from the literature, these latter mutations usually appeared in the presence of specific 
mutations: A431V appears in the presence of V82A and/or M46I, and this was also the case for 
this patient. P453L has been described to appear in the presence of I50V, I84V, D30N, N88D 
and L90M (Fun et al., 2012). However, none of these PR mutations were detected in this patient.  
Interestingly, mutations A431V and P453L were acquired when the L10F mutation in the PR 
was acquired.  
For PCSM007, at the 1st time point the gag CS mutations included G381S and A431V. Again in 
this patient A431V appeared in the presence PR mutations V82A and M461 (Table 4.2). After 
two months, a 2nd genotype was performed and these gag mutations were still detected.  
Table 4.4: Mutations occurring in the gag and PR of the patients that remained on 2nd line 
therapy.  
Patient PR mutations Gag mutations 







































G381S, A431V G381S, A431V 
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4.2.3 Correlation of gag mutations with Protease resistance mutations  
To further investigate the association of gag mutations with PR mutations, an analysis of the 
correlations between mutations in gag and PR was done. Unfortunately an association could not 
be made in these patients due to the small sample size, and because most of these patients didn‘t 
harbor PR resistance mutations at either time points. It is expected that with a large number of 
patients a correlation between gag and the PR resistance mutations will be seen.  
4.4 Discussion  
HIV resistance to PIs generally results in impaired PR function and also decreased replication 
capacity of the virus and this loss of replication capacity has been reported to be recovered by 
compensatory mutations that occur in the PR natural substrate i.e. the gag region (Dam et al., 
2009). These mutations have also been reported to play a role in development of PI resistance 
(Clavel and Mammano, 2010, Dam et al., 2009). To investigate this, the mutations occurring in 
the gag region were also analyzed and the association of these mutations with PR resistance 
mutations was examined, particularly because some of the patients did not have any PI 
mutations. 
In this study, we found that all the patients harbored gag mutations at both time points. These 
mutations have been described to be associated with PI resistance (Clavel and Mammano, 2010, 
Dam et al., 2009, Fun et al., 2012, Gatanaga et al., 2002). However, mutations V35I, G123E and 
G381S are rarely described in the literature and were seen in isolates before PI exposure. H219Q 
observed in PCSM009, has been described to be selected during PI exposure (Fun et al 2012). In 
addition, some studies have reported that this mutation is associated with PI resistance mutations 
I54V/L and I84V (Giandhari 2010) unpublished thesis. 
For the patients that were switched from a 1st to 2nd line therapy, none of the patients harbored PI 
resistance mutations when switched on to 2nd line therapy, however they harbored gag mutations. 
It has been reported that the increased polyprotein processing as a results of mutations occurring 
in the gag rather than in the PR itself shows a novel mechanism by which HIV-1 could cause PIs 
resistance in the absence of PR resistance mutations (Ghosn et al., 2011, Nijhuis et al., 2007). In 
a study by Nijhuis et al., 2007 showed that some of the patients that did not harbor mutations in 
the PR region; harbored gag mutations (K48E and I437T/V). Similarly, in our study the gag 
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mutations V35I, G123E and G381S were present in the absence of PI mutations. However their 
role in subtype C is unknown.  
It has been shown that PI resistance mutations hardly develop in patients on initial treatment with 
PI therapy (Gardner et al., 2009). This could be due to the high genetic barrier of Lopinavir as 
the development of PI resistance requires more than one drug resistance mutation to develop. 
This could explain the absence of PI mutations in our cohort. Gardner et al., 2009 has shown that 
the development of PI resistance mutations are more frequent in patients with suboptimal 
adherence and had failure to previous PIs (Gardner et al., 2009).  
For the patients that remained on 2nd line therapy, most of the mutations found in gag (A431V, 
L449P and P453L) have been previously described to be associated with PI resistance mutations. 
This suggests that these mutations could be compensatory mutations to PI resistance mutations 
(Nijhuis et al., 2007, Roquebert et al., 2006a). Mutation A431V was common in all the patients 
and it has been reported to be the most frequent gag mutation in patient failing PI therapy (Fun et 
al., 2012). In addition, this mutation has been reported to confer PI resistance in the presence of 
specific PI resistance mutations M46I, L76V, V82A and I84V (Dam et al., 2009, Fun et al., 
2012). These results are consistence with our observations in the PI experienced group 
investigated in this study. The other commonly described mutations were L449P and P453L. 
Again these mutations were reported to occur in the presence of other PI resistance mutations 
(D30N, N88D, I50V, I84V and I54V) (Fun et al., 2012). This suggests that these mutations have 
no effect on PI resistance when they occur alone, thus they act as compensatory mutations (Fun 
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Chapter 5   
Conclusion 
Drug resistance mutations are usually detected by standard genotyping which only detects 
mutations >20% of the viral population but not the minority variants which occur at low levels of 
the viral population. The impact of these minority variants related to drug resistance still remains 
unresolved although there is evidence that these minority variants influence treatment efficacy. 
Thus more sensitive methods such as cloning and UDPS have been used to detect minority 
variants. 
Additional drug resistance mutations were detected by cloning in all the patients studied. Where 
patients switched from 1st to 2nd line regimens, most of the minority variants were detected at the 
2nd time point and these were related to their 1st line therapy, mostly NNRTI mutations, 
indicating that these mutations persist even in the absence of drug selection pressure. In addition, 
where patients remained on a failing PI regimen, PI minority variants were seen at both time 
points. Of note was the increase in L10F frequency in all the patients in this group.  
Furthermore, we also compared the minority variants that were detected by cloning and UDPS. 
While UDPS is more sensitive than cloning from our findings, UDPS yielded similar results to 
cloning with very few additional minority variants detected.  In the isolates where no PI 
resistance mutations were detected by Sanger, cloning or UDPS, this could be due to non-
adherence, in which case this could indicate that minority PI resistance mutations do not persist 
in the absence of drug selection pressure. Alternatively, this could be due to the high genetic 
barrier of PIs as the development of PI resistance takes time to develop. In addition, many 
studies have reported that gag mutations can confer PI resistance in the absence of PI resistance 
mutations. In this study we also identified gag mutations in all the patients, however many were 
present before isolates not exposed to PIs. The A431V, P453L and L449P mutations were only 
seen in the patients that remained on 2nd line therapy PI, with A431V the most frequent.  
Despite the limitations of sample size and availability for UDPS, this study illustrates the 
importance of detecting minority variants in patients failing treatment, to fully assess the drug 
resistance mutations spectrum and their impact on future therapy options. Future studies on 
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associations of gag and PR resistance mutations with increase sample size as well as detecting  
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